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Gastric cancer (GC) is a major malignancy and the second-highest cause of 
death due to cancer. Even though treatment options such as chemotherapy, 
radiotherapy and surgery are available, survival rate of patients are low, which 
in turn creates a burning need to identify novel and efficient chemotherapeutic 
drugs. Natural compounds have been examined for their anti-cancer properties 
since time immemorial. In our study, we examine the anticancer effects of one 
such natural compound, Isorhamnetin, (IH) a 3'-O-methylated metabolite of 
quercetin, on gastric cancer cells, and its potential impact on the PPARγ 
activation pathway. The effect of IH was investigated using a combination of 
in-silico, in-vitro and in-vivo models. We initially utilized a functional 
proteomics tumor pathway technology platform to understand the potential 
activities of isorhamnetin, and later tested the same on gastric cancer cell lines 
and a xenograft mouse model.  
Firstly, using a virtual predictive tumor cell system, we found that IH could 
modulate various genes involved in apoptosis, proliferation and angiogenesis, 
including PPARγ, a nuclear receptor involved in controlling cancer cell 
growth and inducing apoptosis. This led us to hypothesize that IH could act in 
gastric cancer via the PPARγ pathway. Our results demonstrated that IH 
exerted significant cytotoxic effect in both drug sensitive and resistant gastric 
cancer cells. We observed, for the first time, that IH increased PPARγ activity 
and modulated the expression of the PPARγ regulated genes. Also, the 
increase in PPARγ activity was partially reversed in the presence of PPARγ 
specific inhibitor and a PPARγ dominant negative mutant, supporting our 
hypothesis that IH can act as a ligand of PPARγ. We also observed using 
molecular docking analysis that IH indeed formed interactions with 7 polar 
xi 
 
residues and 6 non-polar residues within the ligand-binding pocket of PPARγ 
that are reported to be critical for its activity.  
Our results demonstrate that IH could inhibit transforming growth factor-β 
(TGF-β) induced proliferation, migration and invasion of gastric cancer cells. 
IH modulated the expression of genes such as N-cadherin, E-cadherin, 
Vimentin, Snail and γ-catenin that are involved in regulating epithelial 
mesenchymal transition (EMT), and also down-regulated levels of bone 
morphogenetic receptor protein-2 (BMPR2) in gastric cancer. Clinical analysis 
showed that BMPR2 gene expression correlated positively with gastric cancer 
prognosis and EMT score, thereby indicating its involvement in EMT 
progression. Supporting the clinical results, our in-vitro data showed that 
knockdown of BMPR2 mitigated the migratory potential of gastric cancer 
cells and attenuated EMT whereas over-expression of BMPR2 increased the 
migratory properties of gastric cancer cells.  
We further noted that IH could enhance the cytotoxic effects of chemo-
therapeutic agents against various gastric cancer cell lines, and significantly 
potentiate the antitumor effects of capecitabine in a gastric cancer xenograft 
mouse model, that correlated with suppression of various biomarkers of 
survival and angiogenesis. Overall, our findings clearly indicate that IH 
exhibits significant anti-cancer effects both in-vitro and in-vivo and these 
actions may be mediated at least in part, through the modulation of the PPARγ 
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1. INTRODUCTION  
1.1. Cancer: the silent killer  
Cancers are caused by the abnormal growth of cells that arise from normal 
tissues in the human body, that have lost their capacity to assemble, and 
develop, into tissues of normal form and function [1]. In simple words, they 
can be viewed as a disease of malfunctioning cells. They evolve progressively 
from being a normal cell, to an invasive and aggressive cell type, that make 
them responsible for a huge number of deaths worldwide [2]. Research shows 
that one in three people in developed countries continue to be diagnosed with 
this disease before the age of 75 years. Estimates suggest that 12.7 million 
cases of cancer were discovered, and of these, 7.6 million cases led to death 
worldwide in 2008 [3]. According to the International Agency for Research on 
Cancer (IARC), the highest number of these deaths were due to cancers of the 
lung (1.6 million, 19.4% of the total), liver (0.8 million, 9.1%), and stomach 
(0.7 million, 8.8%). Though the number of cancer related deaths is alarming, 
survival rates have improved drastically. With researchers constantly striving 
to bridge the gap between science and medicine, there has been a tremendous 
increase in early detection methods and treatment regimens. Studies show that 
there is an improved survival rate over the past decades, with approximately 
60% of patients living over 5 years after diagnosis [4]. However, the 
complexities of cancer environment often make it difficult to settle on an 
effective mode of treatment.  
            Even though cancers are strongly regarded as evasive and 
unpredictable, hallmark characteristics of cancers have been determined, 
thanks to the continuing research on this disease. These are excessive cell 
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growth, reprogramming of energy metabolism to support uncontrolled 
proliferation, immortality, resistance to cell death, induction of angiogenesis, 
ability to invade and metastasize to distant sites, reprogramming of energy 
metabolism and evading immune destruction [5, 6]. These six hallmarks have 
been extensively used by researchers as a foundation for the in-depth 
understanding of cancer behavior. Even though scientists debate that cancers 
are a plethora of several complex events, and cannot be regarded as resulting 
from a few isolated mutations, the identification of common characteristics of 
different cancers provides us with a unifying theme to ignite our search for the 
‘perfect target’ or a ‘magic bullet’ [7].  
        Though researchers have tried to promote marginal benefits of a single 
agent, to a majority of patients with varied backgrounds, there exists extensive 
biological complexities within the historical classifications of various tumors, 
that make it practically impossible to expect similar efficacy of an agent across 
varied tumors [8]. Solid tumors, that constitute a major percentage of tumors, 
are especially difficult to treat due to their heterogeneity [9]. Hence, 
understanding the molecular basis of a cancer type is an important step in 
determining the perfect therapy. 
 
1.2. Gastric cancer 
Gastric carcinoma (GC) is one such type of solid tumor that arises from the 
inner linings of the stomach. The development of gastric cancer appears to be 
complex, with genetic predisposition, infection, and diet as important factors. 
Though other factors such as smoking and alcohol intake have been linked 
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towards its incidence, the evidence supporting their role is seemingly 
inconsistent [10].  
Currently, five types of gastric cancer are described by the World Health 
Organization (WHO): papillary, tubular and mucinous adenocarcinoma, 
poorly cohesive carcinoma (with or without signet ring cells) and mixed 
carcinoma [11]. They have been classified into two major types (known as 
Lauren’s classification), the diffuse and intestinal types, that stand for two 
different epidemiological and pathological entities [12]. Generally, intestinal-
type appears to be well differentiated with cohesive tumor cells, while the 
diffuse-type is poorly differentiated with non-cohesive tumor cells [13]. 
 
Fig 1. Histological subtypes of gastric cancer  
(A) Intestinal type gastric cancer, characterized by infiltrating tubular profiles.  
(B) Diffuse type carcinoma in which there is diffuse infiltration of the mucosa. 
In this case, there is no significant sign of metaplasia. Both images were 
stained with haematoxylin and eosin and pictures obtained at magnification 




1.2.1. Risk factors and epidemiology of Gastric Cancer 
Gastric cancer has the 2nd highest cancer-related mortality rate worldwide 
[14]. The risk of developing gastric cancer is said to be 1 in 115, possessing a 
survival rate of about 20-30% only [15]. The low survival rate has been often 
attributed to a delay in diagnosing the presence of cancer, usually only at a 
point when the tumor has already metastasized. However, the seemingly dark 
situation has begun to brighten, owing to the establishment of screening 
programmes for early diagnosis and careful surgical resection [10]. According 
to the International Agency for Research on Cancer, gastric cancer has the 
sixth highest incidence of cancer in Singapore with equally high mortality 
rates.  The highest risk of developing gastric cancer is thought to occur 
through the infections with Helicobacter pylori (H pylori), a gram bacillus, 
discovered by Marshall and Warren in 1983 [16]. A recent study has 
suggested that H. pylori can introduce host genome instabilities either directly, 
or indirectly through epigenetic modifications, and these seem to be reduced 
following its eradication [17]. Other risk factors for gastric cancer include diet 
and genetic abnormalities in the host environment. For example, it was 
observed in a study in Portugal, that patients with high salt intake were at 
higher risk of gastric cancer development as compared to those with lesser salt 
intake [18].  
 
1.2.2. Diagnosis of gastric cancer  
Diagnosis of gastric cancer continues to be a difficult feat for physicians. This 
is attributed to the fact that patients at an early stage of gastric cancer are 
invariably asymptomatic. However, the symptoms that are commonly 
observed at a later stage include weight loss, dysphasia, dyspepsia, vomiting, 
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early satiety, and/or anemia [19]. An experienced pathologist usually 
diagnoses the disease by a gastroscopic or surgical biopsy, and generates a 
histology report according to the World Health Organization criteria [IV, C]. 
More than 85% of gastric cancers are found to be adenocarcinomas, 
and as mentioned earlier, these are classified according to histology into 
diffuse and intestinal types. The Clinical Practice Guidelines are not 
applicable to less commonly observed gastric malignancies such as 
gastrointestinal stromal tumors (GIST), lymphomas and neuro-endocrine 
tumors. Although less useful in antral tumors, endoscopy (EUS) has been 
widely used to find the proximal and distal extent of the tumor, while 
laparoscopy is utilized in all stages of stomach cancers [20].   
 
1.2.3. Treatment modalities for gastric cancer  
1.2.3.1. Surgery  
The primary method of treatment of early stage patients is through surgery. 
Endoscopic resection is also used as an alternative for treatment in well-
differentiated early stage tumors [21]. Though there is an ever-growing 
interest in the use of minimally-invasive techniques for gastric resection, 
clinicians have to ensure that the outcome is similar to the highly positive 
results usually achieved through an open surgery [22]. To decide if patients 
require a combination of surgery and multi-modal therapies, surgeons require 
improved predictors of nodal disease and prognosis. Studies suggest that 
majority of patients benefit through use of surgery followed by neo-adjuvant 




1.2.3.2. Chemotherapy  
Chemotherapy has been accepted as the standard mode of treatment in 
advanced gastric cancer patients and post-operative chemotherapy has 
especially become a standard option in patients treated for gastric cancer in 
Asia [24]. Five classes of cytotoxic agents are currently used in GC treatment. 
They are fluoropyrimidines, platinum compounds, taxanes, topoisomerase 
inhibitors and anthracyclines. Their mechanism(s) of actions are described 
below in brief: 
Cisplatin: Cisplatin is a metallic (platinum) coordination compound that has 
been used for treatment of a variety of cancers. It was the first FDA-approved 
platinum compound for cancer treatment in 1978 [25]. It consists of a doubly 
charged platinum ion surrounded by four ligands; on the left are the amine 
ligands that form strong interactions with the platinum ion, and on the right, 
the chloride ligands or carboxylate compounds that allow the platinum ion to 
form bonds with DNA bases [26]. Cisplatin is significantly toxic, which often 
results in nausea, vomiting, nephrotoxicity, and neurotoxicity [27]. 
Capecitabine and 5-fluorouracil (5-FU): Capecitabine is an oral 
fluoropyrimidine and prodrug which was initially designed to maintain a 
continuous supply of 5-FU, the sole aim being to provide prolonged drug 
exposure and tissue selectivity. It is metabolized in the liver by hepatocyte 
carboxylesterase (CE) to 5′-deoxy-5-fluorocytidine [28]. The active metabolite 
competes with deoxyuridine monophosphate and binds to thymidylate 
synthase thereby inhibiting de novo thymidine synthesis, a phenomenon 
important for DNA replication and cell survival [29]. However, it has side-
effects that include the appearance of hand-foot syndrome, leukopenia, 
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elevated bilirubin and diarrhea [30]. A commonly used combination regimen 
for advanced gastric cancer is 5-fluorouracil (5-FU) in conjunction with 
cisplatin, on a bi-weekly or a tri-weekly schedule [31]. 
Taxanes: Taxanes, which include paclitaxel or docetaxel, act by disrupting the 
microtubule function and inhibiting the process of cell division.  With the 
potential application of taxanes came the use of novel combination regimens, 
such as docetaxel/cisplatin/5-fluorouracil (5-FU) (DCF), which is now being 
utilized as a standard therapy in advanced gastric cancer in a selected cohort of 
patients [32]. Similarly, a combination of paclitaxel with fluoropyrimidines 
and/or platinum compounds show considerable improvement in results as 
compared to mono-therapy [33]. The most common adverse effects observed 
on administration of taxanes are neutropenia accompanied by sustained fever.  
Irinotecan: Irinotecan acts by inhibiting topoisomerase I and thus prevents 
DNA from unwinding. Trials have shown good tolerance and promising 
results although they have been closely associated with toxic effects such as 
diarrhea and neutropenia [34]. A new triplet combination—TIROX, consisting 
of S-1 (oral dihydropyrimidine dehydrogenase, based on a biochemical 
modulation of 5-FU)  in conjunction with irinotecan and oxaliplatin has shown 
a marked reduction of tumor burden from baseline in patients [35].  
 8 
 
1.2.3.3. Molecular targeted therapies 
Gastric cancer is a heterogeneous disease consisting of numerous 
chromosomal aberrations, genetic and epigenetic changes and alterations in 
oncogenic pathways. These have led to the discovery of various targeted 
anticancer agents that are described in brief below.  
Cell surface inhibitors: Angiogenesis is an important part of tumor 
progression and Vascular Endothelial Growth Factor (VEGF) is a critical 
factor in this phenomenon. It has an essential role in physiologic and 
pathologic angiogenesis, making it an attractive target for growth inhibition 
[36]. Bevacizumab is a recombinant humanized IgG1 monoclonal antibody 
against VEGF which is extensively used in combination with chemotherapy 
[37]. Sunitinib is an oral, multitargeted tyrosine kinase inhibitor of VEGF 
receptor, approved for the treatment of advanced renal cell carcinoma (RCC) 
and imatinib-resistant gastrointestinal stromal tumors (GIST). Even though 
these drugs are widely used in practice today, there are major drawbacks 
associated with them. VEGF pathway is critical for the physiological functions 
and homeostasis of the cell, which are disturbed with the use of its 
pharmacological inhibitors. The adverse effects associated with the VEGF 
inhibitors include hypertension, arterial thrombosis, cardiomyopathy and 
impaired wound healing [38]. Sorafenib is yet another inhibitor of Raf tyrosine 
kinase that is used in the treatment of RCC and hepatocellular carcinoma [39]. 
However, patients typically experience hypertension and cardiac ischemia as 




Epidermal Growth Factor Receptor blockers: EGFR is a transmembrane 
glycoprotein receptor (EGFR) family of extracellular protein ligands and is 
overexpressed in several GI malignancies. It is activated and phosphorylated 
as a result of ligand binding, that results in the activation of Ras/Raf/mitogen 
activated protein kinase (MAPK) pathway or the Akt/mTORpathway. 
Cetuximab is an IgG1 type chimeric monoclonal antibody that competitively 
inhibits the binding of EGF to its receptor [41]. Even though proven to be 
effective, it has been associated with skin toxicity, including skin rash, dry 
skin, hair growth disorders, pruritus, and nail changes that can severely affect 
the well-being of patients [42].  
                   Gefitinib is an orally active EGFR tyrosine kinase inhibitor with 
promising activity against a range of malignancies in early phase trials 
[43].The common adverse drug reactions of gefitinib include diarrhea and skin 
rash, which are generally mild and reversible. A small percentage of people 
have also reported to experience fatal interstitial pneumonia [44]  
 
Human Epidermal Growth Factor Type 2 Inhibitors: HER-2 is a member 
of the EGFR family and is active in promoting tumor progression [45]. 
Trastuzumab, a monoclonal antibody against HER-2, is the only validated 
receptor tyrosine kinase inhibitor in gastric cancer, while lapatinib is an oral, 
small molecule, dual tyrosine kinase inhibitor of EGFR and HER-2, found to 
be effective in trastuzumab-resistant advanced breast cancer [46].      
               Other molecular targeted agents include the inhibitors of insulin-like 
growth factor, c-Met tyrosine kinases and fibroblast growth factor tyrosine 
kinases. Several other drugs have also been developed that target cell-cycle, 
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Ubiquitin–proteasome pathway, heat shock protein 90 as well as matrix 
metalloproteinases [11].  
            Even though several pharmacological inhibitors have been developed 
to target various oncogenic molecules and their downstream signaling 
cascades, given the highly complex nature of cancers, targeted therapy has not 
been as successful in reality as it was expected to be. Hence, it is imperative to 
develop a multi-targeted approach, possibly by employing a combination of 
agents with non-overlapping mechanisms(s) of action, but the chances of it 
becoming a reality is hampered by the limited knowledge on the kind of 
efficacious agents that can be used in combination, the inability to design or 
test on multi-sponsor clinical trials, as well as the added toxicities associated 





1.2.4. Gastric cancer pathogenesis  
Gastric carcinoma is caused by a complicated interaction of the host, 
environment and bacterial factors. Helicobacter pylori is a human gastric 
pathogen that causes gastric inflammation and is etiologically related to gastric 
adenocarcinoma [48]. H. pylori gastritis possesses various inflammatory 
infiltrates including neutrophils, lymphocytes, plasma cells, eosinophils, 
macrophages, and mast cells. The infection typically results in a life-long 
acute and chronic inflammatory response that leads to progressive mucosal 
damage. This causes the development of different types of metaplastic and 
dysplastic epithelia that eventually result in gastric adenocarcinoma [49].      
                Studies have suggested that H. pylori-infected individuals whose 
diet consist of minimal fresh fruits and vegetables, combined with excessive 
use of food preservatives and salt have a greater tendency to develop 
progressive atrophy, which is linked to gastric ulcers and ultimately to gastric 
cancer. On the contrary, individuals with continuous access to fresh fruits and 
vegetables, with a healthy diet, have comparatively less mucosal damage and 
lower incidence of gastric cancer [50]. However, it is interesting to note that 
even in places of low incidence, gastric cancer has an ability to develop in the 
presence of polymorphisms in the host coupled with a virulent strain of H. 
pylori. In conclusion, even though H. pylori host interactions play an 
important role in gastric cancer pathogenesis, bacterial virulence seems to be 
the key factor in predicting the disease outcome.  
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1.2.4.1. Helicobacter pylori virulence factors and their role in gastric 
cancer pathogenesis 
There exist several putative virulence factors such as CagA, vacuolating 
cytotoxin (VacA), OipA and DupA in H. pylori that play a pivotal role in 
gastric cancer pathogenesis. Out of these factors, CagA, is a highly 
immunogenic protein that has been incorporated into H. pylori by horizontal 
transfer. The expression of CagA in H. pylori varies greatly, from 100% in 
East Asia to less than 50% in some western countries. Research has shown it 
can function as an oncogene; transgenic mice containing CagA has been 
shown to spontaneously develop gastric cancer [51].  
        VacA is a factor that is present in almost all strains of H. pylori. It 
possesses diverse biological functions, such as membrane channel formation, 
release of cytochrome c from mitochondria, initiation of a pro-inflammatory 
response and specific inhibition of T-cell activation and proliferation [52]. 
Expression of VacA has been consistently associated with the extent and 
severity of inflammation. OipA is an adhesion, pro-inflammatory response-
inducing protein that can induce IL-8 from gastric epithelial cells. It is shown 
to be involved in the phosphorylation of three different families of mitogen 
activated protein kinases, namely p38, JNK and ERK [53, 54]. It is also 
thought to be involved in β-catenin signaling that modulates cell–cell 
junctions and cell proliferation [55]. H. pylori either produces all of these 
proteins or none of them, and clinical outcome depends on the strain and the 
virulence factors associated with it. However, the presence of the above 
indicated factors has been found to directly increase the aggressiveness of the 





Fig 2. Role of Helicobacter pylori in gastric cancer pathogenesis 
 
H. pylori attaches to the gastric epithelial cells, and through its type 4 
secretion systems (T4SS), CagA is delivered to them. CagA is in turn tyrosine 
phosphorylated at EPIYA sites initially by SRC and later by ABL kinases. A 
combination of the effects of the two proteins, CagA and VacA can contribute 
to gastric carcinoma development. Adapted from Cancer Lett. Sep 8, 2009; 
282(1): 1–8. 
 
A number of publications have analyzed the role of diverse pro-inflammatory 
pathways that are enhanced after bacterial infection, whereas only few studies 
have focused on characterizing the counter-balancing, anti-inflammatory 
response generated inside the body. An important study deciphered the role of 
a transcription factor, peroxisome proliferator-activated receptor-γ (PPARγ) as 
one of the various anti-inflammatory mediators in gastric cancer [56]. The 
relationship between PPARγ, its regulated genes and their non-inflammatory 
actions in gastric cancer will be discussed in the forthcoming chapter. 
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1.2.4.2. Genetic mutations in gastric cancer  
Similar to the profiles of other cancers, gastric cancer is found to be 
heterogenic, with each patient exhibiting distinct genetic and molecular 
characteristics [57]. It is now necessary to use advanced molecular methods to 
identify the optimal method of treatment of gastric cancer, with its complex 
histological and molecular aberrations [58].  
            For example, next generation sequencing is a powerful tool for 
identifying potential therapeutic targets and improving personalized treatment 
options [59]. Wang and colleagues were the first to publish an exome-
sequencing study in gastric cancer that identified 20 genes as top candidate 
drivers, of which the major finding was the identification of high mutation 
frequency of ARID1A [60]. Later, Zang et al. confirmed the same, and also 
identified FAT4, a member of the E-cadherin family as a strong candidate 
driver gene [61]. In 2012, Kim et al. showed using RNA-seq study that the 
central metabolic regulator AMPKα2 (PRKAA2) is a potential functional 
target in Asian gastric cancer [62]. Only a handful of publications are present 
that currently describe the potential molecular basis of gastric cancer through 
NGS. Nevertheless, they provide tremendous insight into the understanding of 
the genetic alterations in gastric cancer. Further, The International Cancer 
Genome Consortium (ICGC) has aimed to systematically study 25,000 cancer 
genomes at the genomic, epigenomic, and transcriptomic levels for at least 50 
cancer types, which will serve as valuable resources for identifying novel 
targets in gastric cancer. 
 15 
 
1.3. Peroxisome proliferator-activated receptors 
1.3.1. Peroxisomes proliferators and the discovery of PPARs 
Peroxisomes, referred to as glyoxysomes or microbodies in plants, are 
versatile organelles present in eukaryotes that play a critical role in many 
metabolic pathways [63]. These are related to lipid metabolism, involving β-
oxidative degradation of fatty acid, synthesis of cholesterol and other 
isoprenoids, and synthesis of glycerolipid (plasmalogen). They are dynamic, 
with the capacity to change their appearance, their association with other 
organelles, and their enzyme composition [64].  
          Later studies discovered that peroxisomes respond to a variety of 
chemical agents, known as peroxisome proliferators (PP), which are a diverse 
group of chemical entities with various applications. As the name suggests, an 
increase in rate of proliferation and the number of S-phase cells have 
frequently been observed when treated with these agents. These compounds 
include clofibric acid and methylclofenapate [65], and nafenopin [66], some of 
the first identified peroxisome proliferators. Though these chemicals have 
been thought to act as hepatocarcinogens in rats, they do not elicit a similar 
response nor have carcinogenic risk in humans [66].  
         The peroxisome proliferators were first discovered to activate a form of 
peroxisome-proliferator activated receptor (PPAR) called PPARα, which is 
found to be abundant in the liver. PPARs belong to a family of nuclear 
hormone receptors and the activation of PPARα was found to be responsible 
for the pleiotropic effects of PPs seen in rodents, such as enzyme induction, 
hepatocyte DNA synthesis and suppression of hepatocyte apoptosis [67]. 
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1.3.2. Structure of PPARs  
Nuclear hormone receptors consist of a large family of ligand-modulated 
transcription factors including the steroid and thyroid hormone receptors 
(TRs), the retinoid hormone receptors, and ‘orphan’ receptors (receptors 
whose ligands have not been identified yet) [68]. They modulate the 
expression of various target genes by binding to specific DNA sequences, 
(called response elements) present in the promoter of these genes [69].  
Extensive study of amino acid sequences of various steroid hormone 
receptors led to the identification of four characteristic domains: the N-
terminal A/B domain that comprises of a ligand-independent transactivation 
function, called activation function 1 (AF-1); the highly conserved C domain 
containing the DNA-binding domain (DBD); the D domain or so-called “hinge 
domain”, linking the DBD to the ligand-binding domain (LBD); and, the C-
terminal E/F domain or LBD, containing a ligand-dependent transactivation 
function, termed AF-2 [68].  
 
Fig 3. Schematic diagram of the common domain structure of nuclear 
receptors  
Similar to other nuclear receptors, PPAR gamma contains an N-terminal 
activation function 1 (AF-1), DNA binding domain (DBD) consisting of two 
zinc fingers (ZF), non-conserved hinge-region (Hinge), ligand binding domain 
(LBD), and C-terminal AF-2 helix. Adapted from FEBS Lett. Jan 9, 2008; 
582(1): 2–9.  
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1.3.3. Types of PPARs 
Peroxisome proliferator-activated receptors (PPARs) include 3 members: α, 
β/δ, and γ, and each of them act as a heterodimer with retinoid-X-receptor 
(RXR). As described earlier, PPARα, was the first PPAR to be identified, and 
is the target of the fibrate-class of anti-hyperlipidemic drug or peroxisome 
proliferators [70]. It is abundantly found in the liver, heart, muscle and kidney 
where it regulates fatty acid oxidation and apolipoprotein synthesis. PPARα is 
also thought to play an important anti-inflammatory role, being present in the 
vascular wall and human macrophage foam cells [71].  
    Of the three sub-types, PPARβ/δ seems to be the least studied/explored. It is 
ubiquitously expressed and responds to polyunsaturated fatty acids. PPARδ 
activation has been shown to induce mitochondrial fatty acid oxidation, energy 
expenditure and thermogenesis [72]. Deficiency of this receptor promotes 
obesity and insulin resistance, whereas overexpression protects from diet-
induced obesity.  
           The last subtype, PPARγ has been reported to be the ‘master regulator’ 
of adipogenesis and is most abundantly expressed in the adipose tissue. 
PPARγ is also abundantly expressed in foam cell macrophages in human 
aortic atherosclerotic lesions, where they decrease atherosclerosis in mice 
[73].  Overall, it is interesting to observe that all types of PPARs are found to 
be actively involved in suppressing the inflammatory gene expression in 
macrophages. This activity of PPARs has also been linked positively to the 
inhibition of inflammation caused by H. pylori infection.  
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1.3.4. Mechanism (s) of action of PPARs  
In the classical model of PPAR activation, PPAR forms a heterodimer with 
RXR nuclear receptor that further binds to PPRE (PPAR regulatory element) 
termed DR-1, which consists of direct repeats of AGGTCA separated by a 
single intervening nucleotide [74]. This activation could be inhibited by the 
presence of co-repressor proteins [75], such as nuclear receptor co-repressors 
(NCoR), histone deacetylases (HDAC), and G-protein pathway suppressor 2 
(GPS2). Ligand binding causes the dissociation of the co-repressor proteins 
followed by the recruitment of co-activators such as PPAR co-activator (PGC-
1), the histone acetyltransferase p300, CREB binding protein (CBP), and 
steroid receptor coactivator (SRC)-1 [76]. The kind of heterodimer formed 
influences promoter recognition on the target gene sequences and determines 
the effect on different metabolic processes [77].       
 
 
Fig 4. PPARγ binds to RXR receptor to initiate gene transcription  
 
Ligand binding to PPARγ results in the formation of a heterodimer with RXR. 
This heterodimer in the presence of co-activators or co-repressors binds to the 
PPRE region to initiate transcription of relevant genes.  
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1.4. The role of PPARγ activation in H. pylori infection 
As discussed in the previous section, several studies have demonstrated that 
PPARγ has an anti-inflammatory role under physiological conditions. The 
logical mechanism of its anti-inflammatory role is possibly via inhibition of 
diverse pro-inflammatory pathways thereby modulating the expression of pro-
inflammatory genes. An important study reported that activation of PPARγ 
suppresses H. pylori-induced apoptosis in gastric epithelial cells and attributed 
this effect to the direct inhibition of H. pylori-induced NF-κB activation [78]. 
Yet another group reported that use of a potent PPARγ agonist, ciglitazone can 
inhibit gastric mucosal inflammation, as evidenced by reduced apoptosis, 
reduced expression of COX-2, and a drop in the levels of inducible nitric 
oxide synthase (NOS-2) [79].  
           A potent virulence factor which is necessary for inflammatory changes 
in the host is H. pylori lipopolysaccharide (LPS). It functions by inducing 
gastric epithelial cell apoptosis and increasing pro inflammatory cytokine 
production [80]. This induction of proliferation is strongly linked to 
transactivation of epidermal growth factor (EGFR). Interestingly, ciglitazone 
has been shown to suppress this aberrant EGFR activation caused by infection 
of H. pylori [81].  
           Various research groups have also reported that PPARγ is expressed 
and functionally active in gastric epithelial cell lines sensitive to H.pylori-
induced apoptosis, and ligand activation of the receptor could effectively 
attenuate the apoptotic action of H.pylori on gastric epithelial cells [82]. Taken 
together, these studies emphasize the positive role of PPARγ activation in the 
inhibition of H.pylori induced inflammation.  
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1.4.1. Role of PPARγ in gastric cancer  
The scientific evidence related to the involvement of PPARγ in cancer remains 
controversial. It is interesting to note that several groups have reported on its 
pro-tumorigenic role, as opposed to many others who stand by its role as a 
tumor-suppressor. Several in-vitro studies show that PPARγ activation might 
effectively inhibit the proliferation, prevent metastasis and induce apoptosis in 
gastric cancer cells [83, 84]. Takahashi et al. first demonstrated that activation 
of PPARγ in a human gastric cancer cell line, MKN45, that has high 
expression of PPARγ mRNA and protein, inhibited cell growth and induced 
apoptosis in gastric cancer cells [85]. Yet another research group reported that 
PPARγ is also expressed in surgically resected specimens, obtained from well, 
moderately, and poorly differentiated gastric adenocarcinomas, as well as in 
non-cancerous gastric mucosa with intestinal metaplasia [86].  This inhibitory 
effect of PPARγ on gastric cancer may be due to diverse molecular 
mechanisms.  
Ligand-induced activation of PPARγ was found to inhibit c-MET [87] 
and the expression of cyclin D1 and COX-2 [88]. It could also up-regulate the 
expression of various proteins such as p27 [89], p21, and p53 [90] and could 
suppress the expression of gastrin. Thus, the pleiotropic ability of PPARγ to 
inhibit proliferation and metastasis, and induce apoptosis, renders it an 
attractive target for cancer therapy.  
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1.4.2. PPARγ ligands 
Ligands for PPARγ can be either natural [91] or synthetic [92] in nature.  
Synthetic ligands have been developed by researchers through a combination 
of screening, molecular docking with the protein, in-vitro and in-vivo 
validation [93, 94]. Though several synthetic ligands have been routinely 
screened for PPARγ, the only approved use for PPARγ ligands so far is the 
application of thiazolidinediones (full PPARγ agonists) in type 2 diabetes. 
These drugs were first used to treat type 2 diabetes in 1990 by decreasing 
insulin resistance [95].  
               Several drugs fall into the category of thiazolidinediones, of which 
troglitazone, was the first approved drug which became available in 1997 and 
was later withdrawn in 2000 because it induced severe to fatal hepatotoxicity 
that outweighed its so-called ‘benefits’ to diabetic patients [96, 97]. Other 
drugs in the family, rosiglitazone and pioglitazone, are still in clinical use in 
many countries for glycemic control in the treatment of type 2 diabetes. 
However, there still exists an uncertainty about the cardiovascular side-effects 
of rosiglitazone [98], since its treatment has shown an increase in the 
myocardial infarction and heart failure [99]. Compared to rosiglitazone, 
pioglitazone has beneficial effects [100], with lower risk of heart failure, but is 
still limited by occurrence of several adverse effects such as body-weight gain 
and fluid retention [101]. 15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is an 
endogenous ligand for PPARγ produced from a sole precursor, PGD2, and is 
known to affect the expression of various PPARγ regulated genes regulating 
relevant transcription factors [102].  
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1.4.3. Natural sources of PPARγ ligands 
The drastic failure of thiazolidinediones in the market was unexpected by 
researchers, and henceforth, various studies have tried to elucidate the reason 
for such severe adverse effects. It has been suggested that this could be due to 
a result of full PPARγ activation in contrast to the weak agonistic effect of 
natural ligands [103]. Thus, there began a search for the perfect PPARγ 
agonist with enhanced activation but reduced side-effects, commonly referred 
to as selective PPARγ modulators or SPPARMs [104]. Weak activators of 
PPARγ, or partial agonists, elicit the same activation pattern as full agonists 
but with lower maximal activity [93].  
Natural compounds from plants have been used for the treatment of 
various diseases since ancient times. Till today, they are an important source 
for discovery and development of new drugs owing to their rich structural 
diversity [105]. Therefore, there has been a significant interest in assessing 
natural compounds as alternatives to full agonists that seem to elicit severe 
side effects. Several active compounds identified in diet, such as amorfrutins 
[106] and norbixin [107]  are weak agonists per se, but it is suggested that 
their metabolites may have a higher efficiency in inducing PPARγ activation. 
An example is the red clove extract, whose metabolites have been shown to 
have up to 100-fold higher PPARγ binding affinity than their precursors [108]. 
 Quercetin is one such flavonol compound that has been studied to 
partially activate PPARγ and exert beneficial effects on hyperglycemia of 
diabetic animals [109]. Isorhamnetin is a 3'-O-methylated metabolite of 
quercetin, and we aimed to investigate its effect on the PPARγ signaling 
cascade in our study. 
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1.4.4. Flavonoids as PPARγ agonists 
Flavonoids are naturally occurring plant polyphenols that can perform a wide 
variety of biochemical and pharmacological functions [110]. Several agents 
have been identified as PPARγ agonists, of which a few are discussed below. 
Luteolin was found to display weak PPARγ agonist behaviour when compared 
to rosiglitazone, and strong anti-inflammatory activity in the corneal epithelial 
and endothelial layers [111]. Another flavonoid known as baicalin, isolated 
from Scutellaria baicalensis, induced PPARγ activity and suppressed NF-κB-
induced inflammatory response in aging rats [112]. Another study described 
the isolation of 12 compounds and one PPARγ agonist from Chromolaena 
odorata, an invasive weed used in traditional Vietnamese medicine [113].  
 
1.4.5. Application of flavonoids in gastric cancer therapy 
There are numerous studies on the effect of flavonols in cancer and the interest 
in them continues to expand with every passing decade. Flavonoids, and 
natural products in general, have been gaining attention in the treatment of 
cancer not only because they serve as a source of validated structures for 
further discoveries but also due to their relatively low cost and fewer adverse 
effects [114]. Flavonoids are divided into seven different groups; flavones, 
flavonols, flavanones, isoflavones, catechins, anthocyanins, and chalcones. In 
the following section, we will briefly discuss the reported anticancer effects of 
a few selected flavonoids against gastric cancer.  
              Apigenin, one of the most common flavonoids found in abundance in 
celery, passion flower, and other vegetables and fruits has been shown to 
inhibit H. pylori-induced atrophic gastritis and gastric cancer progression as 
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well as possessing potent anti-gastric cancer activity [115]. Soybeans contain a 
major isoflavone, genistein that has been found to exhibit anti-carcinogenic 
properties; it can induce G2/M cell cycle arrest in gastric cancer cells through 
the decreased Ser473 and Thr308 phosphorylation of Akt and upregulation of 
PTEN [116].  Anthocyanins, a group of polyphenols present in many fruit and 
flowers, are proven antioxidants and chemopreventive agents that were shown 
to have protective effects against H. pylori-induced inflammation [117].          
         Casticin, a polymethoxyflavone derived from Fructus viticis has been 
shown to induce DR5 expression in gastric cancer cells, and thus potentiate 
TRAIL-induced apoptotic cell death in gastric cancer cells [118]. Nobiletin is 
yet another typical polymethoxyl flavone from citrus fruits, which can 
enhance the action of 5-fluorouracil in p53 mutant tumors [119]. Eupatelin, 
derived from Artemisia asiatica has been found to reduce pro-inflammatory 
cytokine mediated MMP expression in gastric cancer [120]. Alpinetin is a 
natural flavonoid widely distributed in Zingiberaceae that can alter 
mitochondrial membrane potential leading to release of cytochrome c from 
mitochondria, activation of caspase family members and ultimately leading to 
the apoptosis of human gastric cancer cells [121]. Taken together, these 
studies emphasize the potential of flavonoids in inhibiting proliferation and 
inducing apoptosis in gastric cancer cells.  
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1.5. Isorhamnetin: A novel natural agent 
Isorhamnetin (IH), an immediate metabolite of quercetin, also called 3′-O-
methylquercetin, has gained significant attention of late, for its anti-
inflammatory and anti-proliferative properties in a wide variety of cancers, 
including colorectal, skin and lung cancers [122-124]. Prior studies so far have 
focused on quercetin as an anti-inflammatory agent, but recent research has 
shown that isorhamnetin can induce greater cytotoxicity in tumor cells as 
compared to quercetin [122]. For example, it was found that aflatoxin B1 
(AFB1)-mediated reactive oxygen species (ROS) generation was abrogated 
significantly by isorhamnetin when compared to quercetin in hepatocellular 
carcinoma cells [125]. 
 
Fig 5. (A) The chemical structure of isorhamnetin (MW: 316.26 g/mol)  
 





1.5.1. Role of isorhamnetin in inflammation 
Of the various beneficial roles of isorhamnetin, its anti-inflammatory role has 
been studied in detail by researchers across the globe. A study reported that 
isorhamnetin could induce heme oxygenase-1 by that lead to reduction in ROS 
production which in turn resulted in the inhibition of COX-2 expression in 
response to inflammatory stimuli [126]. Another study also described that 
isorhamnetin could reduce inducible nitric-oxide synthase (iNOS) expression, 
and suggested that this might be mediated by inhibition of NF-κB activation 
[127]. The results were supported by another research group, which reported 
that this 3′-O-methylated flavonoid could inhibit JNK and AKT/IKKα/β 
phosphorylation and in turn inhibit the effect of NF-κB regulated genes such 
as TNF-α, IL-1β and IL-6 [128].  
          Similar to our hypothesis of involvement of isorhamnetin in inducing 
PPARγ activation, a group reported that the treatment with Eruca sativa 
extract, which contained isorhamnetin, could significantly increase the 
transactivation activity of PPARα and thereby suppress the expression of 
inflammatory cytokines and antimicrobial peptides [129]. A recent review 
suggested that isorhamnetin might play a fundamental role in inhibiting 
inflammation, possibly through its targeted effects on a combination of pro-
inflammatory pathways [130]. Based on existing evidence, it is suggested that 
isorhamnetin reduces inflammation primarily by inhibiting COX-2 expression, 
an effect that is quite common among flavonoids [131].  It has been reported 
that the O-methylated group in isorhamnetin, could effectively increase the 
plasma bioavailability of this flavonoid, by preventing the rapid metabolism as 
it undergoes glucuronidation and sulfation [132]. In fact, the chemopreventive 
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role of methoxy-flavones have been discussed in detail previously by Dr. 
Thomas Walle who concluded that the oral bioavailability would be much 
greater for methoxyflavones as compared to the non-methylated flavones 
[133]. These desirable characteristics of isorhamnetin make it an attractive 
agent to be explored further for its potential anticancer effects.  
 
1.5.2. Role of isorhamnetin in cancer 
Prior reports on isorhamnetin clearly indicate that it can exhibit significant 
anticancer effects through the modulation of various oncogenic molecular 
targets in different cancers [134, 135]. For example, a study showed that 
isorhamnetin can suppress skin cancer by binding to and inhibiting MAP 
(mitogen-activated protein)/ERK kinase (MEK) 1 and PI3K. In the same 
study, researchers found that among the four flavonols commonly consumed 
by humans, namely, isorhamnetin, quercetin, rutin, and myricetin, 
isorhamnetin could reduce inflammation, cell proliferation, tumor burden and 
mortality in a mouse model for colorectal cancer [134]. This observation in 
colorectal cancer cells is supported by yet another study by Jaramillo et al. that 
also showed that isorhamnetin could induce significant cytotoxic effects in 
colorectal cancer cells [136].  
            In an identical study, it was reported that this flavonol compound could 
effectively inhibit proliferation and induce apoptosis in human esophageal 
squamous carcinoma cells, though the exact mechanism was not discussed 
[137].  Yet another study reported that this flavonol could induce substantial 
apoptosis in Lewis lung cancer cells through mitochondria-dependent caspase 
activation [138]. An animal model used by the group showed a significant 
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decrease in tumor size and weight upon treatment with isorhamnetin in tumors 
excised from LLC bearing C57BL/6 mice.  
                This plant flavonol can act by modulating multiple molecular 
targets, as demonstrated by another study which reported that isorhamnetin 
exhibited its anticancer effects primarily acting via MEK and PI3-K in non-
melanoma skin cancer [139]. In the same study, isorhamnetin was found to 
suppress MEK1 kinase activity through direct binding, and because ERKs are 
substrates of MEK1, the inhibition of MEK1 by isorhamnetin led to the 
inhibition of EGF-induced phosphorylation of ERKs. Moreover, in human 
hepatocellular carcinoma cells, this metabolite of quercetin was reported to 
exhibit significant cytotoxic effects [140] and was found to permeate the cell 
membrane into the cell. An important observation of the study was that 
isorhamnetin was not converted to any active metabolites inside the cell.  
 Overall, isorhamnetin has been found to have pleiotropic anti-cancer 
effects in various cancers, but its mechanism(s) of action has not been clearly 
elucidated till date. Hence, the major objective of our study was to examine 
the potential anti-cancer effects of isorhamnetin, and to investigate in detail its 
underlying molecular mechanism(s) of action using diverse gastric cancer cell 
lines and a xenograft mouse model. 
 29 
 
1.6. EMT in cancer 
1.6.1. Importance of targeting EMT in cancer 
Benign tumors can usually be removed via surgery and treated with the use of 
chemo-therapeutic agents. On the other hand, metastases in tumors are largely 
incurable and therefore account for the majority of deaths due to cancer. 
Various processes are involved in metastasis, of which epithelial–
mesenchymal transition is an important reversible process by which polarized 
epithelial cells convert into motile mesenchymal ones. This process depends 
on microenvironment signals that interact with various regulators to control 
the expression of proteins that are involved in cell polarity, cell-cell contact 
and suppression of epithelial characteristics [141].  
                It is well established that there are three important stages of tumor 
progression; invasion, dissemination and metastasis [142]. The entire program 
is orchestrated by a set of important transcription factors, including Slug, 
Snail, Twist, ZEB1, and ZEB2, which aid in conversion to a mesenchymal 
state by repressing the expression of epithelial markers and inducing 
expression of other markers associated with the mesenchymal state [143]. The 
signaling events that lead to EMT are not clear even today, but it is suggested 
that genetic and epigenetic alterations acquired by a cancer cell during its 
lifetime transform it responsive to EMT-inducing signals [144].  It has largely 
been regarded that role of EMT in tumor progression is mainly through its 
effect on the processes of cancer invasion and metastasis [145]. However, 
studies are now deciphering the active role of EMT in initiation of primary 




Apart from simply initiating metastasis, acquisition of mesenchymal 
characteristics is associated with resistance to drug therapy in certain cancers 
[146]. Considering the clinically important role of EMT in cancer progression, 
it is imperative to identify novel pharmacological agents that can modulate 
this process.  
 
 
Fig 6. Functional role of EMT in cancer 
 
EMT is a process of transition of polarized epithelial cells into mobile 
mesenchymal cells. On the molecular level, EMT is defined by the loss of 
cell–cell adhesion molecules (e.g., E-cadherin), downregulation of epithelial 
differentiation markers, and induction of mesenchymal markers such as 
vimentin and N-cadherin. During EMT, cells acquire an invasive capacity to 
breach basement membrane, initiate the multistep process of metastasis, and 
spread throughout the host. 
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1.6.2. Role of Transforming Growth Factor-β (TGFβ) in cancer  
 
Transforming Growth Factor-β (TGFβ) is a multi-functional cytokine that has 
been extensively studied to understand the diverse effects exerted by it on both 
epithelial cells and carcinoma cell populations in-vitro and in-vivo [147]. 
TGF-β is overexpressed in various human cancers and is extensively linked to 
their poor prognosis [148]. It seems to perform a dual role in EMT, adapting a 
tumor-suppressor role in early tumor stage and converting to a tumor promoter 
in advanced stages [149]. It appears that signaling of TGFβ is at a contextual 
level, depending on its environment.  
The superfamily of TGF-β cytokines comprises of over 40 proteins, 
including: TGF-beta (β), activins, inhibins, bone morphogenetic proteins 
(BMPs), and growth/differentiation factors (GDFs) [150].  Specific ligands 
activate the receptors via different molecular mechanism(s). They transmit 
their signals through hetero-tetrameric complexes comprising two types of 
serine-threonine kinase receptor, the type I and type II [151]. After activation 
of TGFβ Receptor I, the signal activates Smad2 and Smad3 proteins (R-Smad 
subclass; receptor regulated Smad) bound to the receptors, by phosphorylation 
of their C-terminal (SXS motif) residues, this complex now targets various 
genes involved in transcription and regulation of EMT [152]. They can also 
function in a Smad-independent manner (non-canonical pathways), by 
activating other pathways, such as the extracellular signal-regulated kinase 1/2 
(ERK1/2) and the p38 MAP kinase (p38 MAPK) [153]. 
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1.6.3. Role of BMPR2 in EMT  
Bone morphogenetic proteins are members of the TGFβ family that have been 
well studied in bone formation and embryogenesis [154]. However, recent 
research has suggested they might possess a pro-tumorigenic role [155]. They 
transmit their signals by binding to the BMP type II receptors in combination 
with distinct type I receptors such as Alks 2, 3 and 6 which in turn  
phosphorylates the Receptor-Smads, Smad1, 5 and 8 [156]. 
  
Fig 7. Possible mechanism(s) of action of BMP in EMT 
 
Bone morphogenetic protein (BMP), a member of the TGF-β superfamily, is 
involved in development, morphogenesis, cell proliferation and apoptosis. 
Dysregulation of BMP signaling has been suggested in tumorigenesis. BMPs 
are hypothesized to bind to two types of transmembrane receptors, BMP type I 
(BMPR-I) and BMP type II (BMPR-II). Both these receptors have intrinsic 
kinase activity. Upon BMP binding, the heteromeric complex between type I 
and II receptors initiates intracellular signaling through phosphorylating 
Smad1, Smad5 and Smad8. Subsequently, these phosphorylated Smads 
associate with Smad4 and translocate to the nucleus to modulate the 
transcription of target genes. Three BMP type II receptors, BMPR-II, activin 
type II receptor (ActRII) and ActR-IIB, have been isolated, the binding 
affinities of ActR-II and-IIB for BMPs are lower than those for activins 
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While BMP7 has been shown to block the effect of TGFβ induced 
cholangiocarcinoma, BMP4 has been shown to induce EMT by upregulation 
of Snail and other EMT regulatory genes [157], showing that they might play 
a paradoxical role in cancer progression based on the cancer environment. 
BMPR2 was also found to be over expressed in two prostate cancer cell lines 
that were observed to have the ability to form osteoblastic lesions in vivo 
[158]. Yet another study showed that BMPRII induced de-epithelialization, in 
response to either cadherin-6B or BMP. Overall, these observations make 






















1.7. HYPOTHESIS AND AIMS 
The anti-inflammatory and pro-apoptotic properties of isorhamnetin have been 
studied in detail in various cancer type(s). However, a systematic investigation 
of its anti-tumor effects in gastric cancer has not been performed so far. Thus, 
having understood the potential of isorhamnetin as an anti-cancer agent 
through an extensive review of literature, we hypothesized that isorhamnetin 
may exhibit its pharmacological effects through the modulation of multiple 
oncogenic molecular targets. 
        Our preliminary in-silico data showed that isorhamnetin has the capacity 
to down-regulate various genes involved in proliferation, anti-apoptosis and 
metastasis in gastric cancer. Therefore, we aimed to analyze if isorhamnetin 
could inhibit the proliferation of both drug sensitive as well as resistant gastric 
cancer cells. We also analyzed the pro-apoptotic properties of isorhamnetin in 
gastric cancer, by examining its effect on various genes involved in inducing 
apoptosis.  
                PPARγ has been shown to be a major regulator of inflammation, 
proliferation and metastasis in gastric cancer. We hypothesized that the anti-
cancer activities of isorhamnetin could be mediated at least partially through 
the modulation of PPARγ signaling pathway. Considering the pivotal role of 
EMT in cancer progression, we further aimed to determine if isorhamnetin 
could inhibit the migratory and invasive properties of gastric cancer cells and 
whether these anti-metastatic effects could be mediated through the inhibition 
of BMPR2, a BMP receptor observed to be involved in bone metastasis in 
aggressive tumors.  
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Lastly, we employed a gastric cancer xenograft model to examine the potential 
anticancer effects of isorhamnetin in-vivo. The mouse model was used to 
understand whether isorhamnetin can also reduce tumor growth and enhance 
the effects of chemotherapy. Overall, our aim was to investigate the anti-
cancer potential of isorhamnetin, and decipher its mechanism(s) of action 




2. MATERIALS AND METHODS  
2.1. Materials 
2.1.1. Cell culture maintenance and transfection reagents 
 DMEM (Dulbecco’s 
Modified Eagle’s 
Medium) 
Hyclone (Logan, Utah, USA) 
 RPMI 1640 (Roswell Park 
Memorial Institute 1640 
Medium) 








Life Technologies (Carlsbad, CA, 
USA) 
 FBS (fetal bovine serum)  BioWest (Miami, FL, USA)  
 Trypsin EDTA Sigma-Aldrich (St. Louis, MO, 
USA) 
 
2.1.2. Cell lines 
Human gastric cancer cells AGS, MKN28, YCC1, oxaliplatin-resistant 
NUGC3 and cisplatin-resistant AZ521 were kindly provided by Prof. Patrick 
Tan (DUKE-NUS Graduate Medical School, Singapore). Human gastric 
cancer SNU5 cells, human head and neck carcinoma cell line CAL27, human 
hepatocellular carcinoma cell line HepG2 and human breast cancer cell line 
MDA-MB-231 were obtained from American Type Culture Collection 
(Manassas, VA). MKN45 gastric cancer cells were obtained from JCRB 
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(Japanese Collection of Research Bioresources), Japan.  HFE-145 normal 
gastric epithelial cells were kindly provided by Dr. Hassan Ashktorab 
(Howard University Cancer Center, Washington, DC). Human androgen-
independent DU145 prostate cancer cell lines were kindly provided by Prof. 
Shazib Pervaiz (Department of Physiology, YLLSOM, NUS). AGS, HepG2 
and CAL27 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% fetal bovine serum and 1X antibiotic-antimycotic 
mixture (100 U/mL penicillin, and 100 μg/mL streptomycin). AZ521, 
NUGC3, SNU5, MKN28, MKN45, DU145, MDA-MB-231 cells and HFE-
145 cell lines were cultured in Roswell Park Memorial Institute 1640 media, 
supplemented with 10% FBS and 1X antibiotic-antimycotic mixture. YCC1 
cells were cultured in DMEM media supplemented with 10% FBS, 1X 
antibiotic-antimycotic mixture and 5mM sodium pyruvate. All the cells were 
maintained at 37°C in an atmosphere of 5% CO2 and 95% air.  
 
2.1.3 (A) Test compounds 
We used the following test compounds in different experiments in our study.  
 




 Troglitazone   
 Sigma-Aldrich (St. Louis, MO, 
USA) 
 GSK0660 
 GW0742        




Cayman Chemicals (Michigan, 
USA) 
 Capecitabine   Duheng International Trading 
Company Ltd., Shanghai, China.  
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2.1.3 (B) Functions of test compounds used in the study 
Test compounds Recognized functions 
5-fluorouracil Irreversible inhibitor of thymidylate 
synthase 
Cisplatin Platinum-containing anti-cancer drug 
Troglitazone Synthetic PPARγ agonist 
GSK0660 Inhibitor of PPARβ 
GW0742 PPARβ agonist 
15d-PGJ2 15-Deoxy-Delta12,14-Prostaglandin 
J2, an endogenous PPARγ ligand 
GW9662 Irreversible PPARγ antagonist 
Capecitabine 5-fluorouracil precursor, thymidylate 
synthase inhibitor 
 
2.1.4. Reagents and Chemicals 
 Propidium iodide (PI) 
 Crystal violet  
Sigma-Aldrich (St. Louis, MO, 
USA)  
 Annexin V-FITC assay kit 
 DAPI (4',6-Diamidino-2- 
Phenylindole, 
dihydrochloride) 
Santa Cruz Biotechnology (Santa 





 SDS (sodium dodecyl 
sulfate) 
 Dimethylformamide 
 The Live and Dead 
Viability/Cytotoxicity 





 Trizol reagent 
 Hoechst stain 
 CXCL12 
 TGFβ 
Pro-Spec-Tany TechnoGene Ltd. 
(Rehovot, Israel) 
 RNAase Roche (USA) 
 Calcein-AM Becton Dickinson (Bedford, MA, 
USA) 
 Chemiluminescence ECL GE Healthcare, (Little Chalfont, 
Buckinghamshire, UK) 
 Immunohistochemistry kit DAKO LSAB kit, Dako 
Corporation, (Carpinteria, 
California, USA) 
 BD BioCoat Matrigel 
Invasion Chamber 
BD Biosciences (Bedford, MA) 
 Luciferase Assay System 
with Reporter Lysis Buffer 
Promega Pte Ltd.  
 
2.1.5. Antibodies  
Antibodies used in the study are listed as follows:  
Antibodies purchased from Santa Cruz Biotechnology (Santa Cruz, CA) are: 
Bcl-2   (sc-509)  
Bcl-xL  (sc-8392)  
Cyclin-D1  (sc-753)  
PARP   (sc-7150)  
PPARγ  (sc-7196)  
VEGF   (sc-057496)  
E-cadherin  (sc-8426)  
N-cadherin  (sc-7939)  
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Snail   (sc-10432)  
Vimentin  (sc-6260)  
PARP  (sc-7150) 
MMP-9  (sc-10737) 
COX-2 (sc19999) 
BMP4  (sc12721) 
β-actin  (A5316) was purchased from Sigma-Aldrich  
γ catenin  (ab12083) was purchased from Abcam while 
Ki-67   (# 9027)  
CD31   (# 3528)  
BMPR2  (#6979)  
p-Smad 3 (#9520)  
Smad 3  (#9513)  
were purchased from Cell Signaling Technology, Inc, Danvers, USA 
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2.1.6. Plasmids, siRNAs and transfection methods 
GAL4-mPPARγ-LBD, GAL4-PPARδ-LBD chimeric constructs and GAL4-
luc reporter plasmid were kindly provided by Dr. Javier F. Piedrafita 
belonging to the Torrey Pines Institute for Molecular Studies, California, 
USA. PPRE X3-tk-luc (three DR1 sites upstream of a luciferase reporter)  
reporter construct and pTA-luc empty vector encoding for mouse PPARγ were 
kindly provided by Dr. Ronald M. Evans (The Salk Institute for Biological 
Studies, San Diego, CA, USA). The complete circular plasmid map of PPRE 
X3-tk-luc as obtained from Addgene (non-profit organization that shares 
plasmids with researchers) is provided below:  
 
Fig. 2.1.6 (A) Circular map of PPRE X3-tk-luc 
 
Dominant negative mPPARγ mutant (pCMX-mPPARγC126A/E127A) was 
generously given by Dr. Christopher K. Glass (University of California, San 
Diego, CA, USA).  
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BMPR2 Human cDNA ORF Clone (RG208673) was obtained from OriGene 
Technologies, Inc., Rockville, MD and the plasmid map provided by the 
company is shown below:  
 
 
Fig. 2.1.6 (B) Circular map of BMPR2 Human cDNA ORF Clone 
  
BMPR2 (ID: 659) Trilencer-27 Human siRNA was also obtained from 
OriGene Technologies, Inc., Rockville, MD. It consists of 3 unique 27mer 
siRNA duplexes of 2 nmol each, which were dissolved in SR30005, RNAse 
free siRNA duplex resuspension buffer, provided by OriGene.  
 
Transfection 
Cells to be transfected were allowed to grow till 70% confluency and left to 
attach to the plate surface for at least 24 hours before transfection. DMEM 
serum free media (DMEM media in the absence of FBS and antibiotics) was 
used to dissolve the plasmids/siRNA and lipofectamine reagents, at required 
concentrations, according to manufacturer’s instructions. On 6 well titer 
plates, 9 µg of plasmid DNA was used, along with 9-12 µL of 
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lipofectamine2000. In 96-well plates, 2.5 µg of DNA was used alongside 1.5-2 
µL of lipofectamine2000. For BMPR2 siRNA transfections, 40 nM of siRNA 
was used along with 9 µL of RNAiMAX. The mixture was then added drop-
wise to all wells, and allowed to remain for 4-6 hours. Following transfection, 
serum-free media was replaced by fresh, serum containing media, and allowed 
to incubate for 48-72 hours. During the incubation, cells were periodically 
assessed for cell death visually. Thereafter, cells were treated with drugs, or 
harvested immediately for further analysis.  
 
2.2. Methods  
2.2.1. Drug treatment  
Isorhamnetin, troglitazone, capecitabine, 5-fluorouracil, GSK0660, GW0742 
and GW9662 were dissolved in 100% DMSO and stored at -20°C where they 
were stable for at least three months. 15d-PGJ2 was dissolved in pure ethanol 
solvent while cisplatin was prepared in pure distilled water. Further dilutions 
were freshly prepared in DMEM or RPMI media as and when necessary. 
Cancer cells required in the study were seeded on to the plates and allowed to 
adhere for a minimum of 24 hours, after which they were treated at various 
doses and time-points, as mentioned in the respective figure legends. 
Thereafter, they were harvested and used for various experiments. 
 
2.2.2. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay 
The cytotoxic effect of isorhamnetin against various cancer cells was 
determined by the MTT assay. 5x103 cells per well were seeded in triplicate in 
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a 96-well plate and allowed to attach overnight in a final volume of 200 µL 
media at 37°C. The following day, cells were treated with indicated 
concentrations of isorhamnetin. They were then allowed to incubate for the 
required time points. At the end of each time point, 20 mL MTT solution (5 
mg/mL MTT in PBS) was added to each well. After 4 hours of incubation in 
the dark at 37°C, 100 µL lysis buffer (20% SDS, 50% dimethylformamide) 
was added and incubated for 2 hours at 37°C. Thereafter, cell viability was 
measured by a Tecan plate reader (Durham, NC, USA) at an optical density of 
570nm. 
 
2.2.3. Molecular docking analysis 
Please refer to Appendix-I 
 
2.2.4. PPARγ competitive binding assay 
A binding assay was performed in a white 384-well polypropylene assay plate 
to test if isorhamnetin could competitively bind to PPARγ using 
LanthaScreen™ TR-FRET PPARγ Competitive Binding Assay kit (Life 
Technologies (Carlsbad, CA, USA). A terbium-labeled anti-GST antibody was 
used to indirectly label a nuclear receptor (NR) by binding to its GST tag. 
When a fluorescent ligand (tracer) binds to the receptor, energy transfer from 
the antibody to the tracer occurs, and a high TR-FRET ratio is observed. 
Competitive ligand binding to the NR is detected by a test compound’s ability 
to displace the tracer from the NR, which results in a loss of FRET signal 
between the antibody and the tracer. The assay was performed with various 
concentrations of isorhamnetin as described in figure legends. Isorhamnetin 
was dissolved in DMSO and incubated for one hour with human PPAR-LBD 
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tagged with GST, terbium-tagged anti-GST antibody and fluorescently labeled 
pan-PPAR ligand (FluormoneTM Pan-PPAR Green). Radiometric emissions 
at 520 nm were normalized against terbium emissions at 495 nm and 
subsequently plotted against the indicated concentrations of isorhamnetin to 
assess its PPARy binding ability The positive control, GW1929 was a kind 
gift from Prof. Shazib Pervaiz, and was analyzed using the same method as 
described above. The curve was plotted using a sigmoidal dose-response 
equation with varying slope using Prism® software from GraphPad™ 
Software, Inc.  
 
2.2.5. Flow cytometric analysis 
To determine the effect of isorhamnetin on the cell cycle, gastric cancer cells 
were first seeded at a density of 2x105 cells per well in a 6-well titer plate and 
incubated at 37°C overnight. They were then treated with isorhamnetin for the 
various time intervals as described in figure legends. Thereafter, cells were 
washed, fixed with 70% cold ethanol, and incubated for 30 minutes in ice. 
Cells were then washed again, resuspended, and stained in PBS containing 
25μg/ml propidium iodide (PI) and RNase and kept in the dark for 30 minutes 
at room temperature. Cell cycle distribution was examined using a CyAn ADP 
flow cytometer (Dako Cytomation) as described previously [159].  
 
2.2.6. Annexin V assay 
Similar to the above described procedures, gastric cancer cells were first 
seeded at a density of 2x105 cells per well in a 6-well titer plate and allowed to 
attach at 37°C overnight. After treatment with isorhamnetin for the indicated 
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time intervals, cells were trypsinized, washed with binding buffer, and 
resuspended in annexin V-FITC and PI containing binding buffer for 15 
minutes at room temperature under dark conditions. Cells were analyzed with 
a flow cytometer (BD FACS Calibur, BD Biosciences, US) and the data 
recorded were analyzed using WINMDI software as described previously 
[160]. 
 
2.2.7. Wound healing assay  
The migration of cells was investigated using a ‘wound-healing’ assay. Gastric 
cancer cells were seeded in a 6-well microtiter plate until about 80% 
confluent. To observe the effects of over-expression or knock down of 
BMPR2, cells were first transfected as described previously (2.1.6) before 
beginning the assay. Using a pipette tip, a ‘wound’ was created on the uniform 
layer of seeded cells, the location of the wound marked on the micro titer 
plate, and each well lightly washed with PBS to remove detached cells. 
Images of the wounds observed under the microscope before treatments were 
recorded. The cells were then treated with specific drugs, or simply allowed to 
migrate for the indicated time-points. At the end of the time-point, the 
microscopic observation of the cells was again recorded to compare the gap 
difference before and after treatment. 
 
2.2.8. Invasion assay 
The BD BioCoat Tumor Invasion system contains a BD FluoroBlok PET 
membrane (8.0 µm pore size) uniformly coated with BD Matrigel™ Matrix 
(BD biosciences). 5x104 gastric cancer cells were suspended in serum-free 
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media and seeded into the Matrigel transwell chambers and allowed to 
incubate overnight. The cells were treated with the required reagents and 
allowed to invade at the time-points indicated in the figure legends. Media 
containing 10% FBS was used in the bottom chamber to act as a chemo-
attractant. In experiments using CXCL12, it was added at this step in the lower 
chamber to facilitate further invasion of cells. Following incubation, the upper 
surfaces of the transwell chambers were wiped with cotton swabs and the 
invading cells were fixed and stained with crystal violet solution. The invading 
cells were then observed under the microscope, and counted in 5 randomly 
selected areas as described previously [160].  
 
2.2.9. Luciferase assay 
The activity of PPAR-γ was investigated using luciferase assay. Firstly, 5x103 
gastric cancer cells per well were seeded in a 96-well micro titer plate and 
allowed to adhere to the plate overnight. The cells were incubated in serum 
free DMEM medium for at least 1 hour followed by transfection with pPPRE-
tk-Luc as described in section 2.1.6.  In the experiment to study the activation 
of PPARs by isorhamnetin, the cells were first transfected with either GAL4-
PPAR-β LBD or GAL4-PPAR-γ LBD plasmids, together with GAL4-Luc. For 
experiments requiring a mutant PPARγ, the cells were transfected with PPARγ 
dominant negative plasmid or pCMX-PPARγ plasmid together with pPPRE-
tk-Luc. Cells were lysed in reporter lysis buffer (Promega, USA) and 
luciferase activity was immediately measured with a Tecan (Durham, NC, 
USA) plate reader and normalized against Renilla activity. The Relative 
Luciferase Unit per µg of each treatment group was then plotted against the 
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control group. The data was analyzed using Prism® software from 
GraphPad™ Software, Inc. 
 
2.2.10. Western blot analysis 
For detection of various proteins, gastric cancer cells were first seeded at a 
density of 3x105 cells per well on a 6 well micro-titer plate and treated with 
isorhamnetin for different time intervals. The cells were then washed with 1X 
PBS and incubated on ice for 30 minutes in 0.05 ml lysis buffer (2.0 mM Tris 
(pH 7.4), 2.50 mM NaCl, 2 mM EDTA (pH 8.0), 0.1% Triton X-100, 0.01 
mg/mL aprotinin, 0.005 mg/mL leupeptin, 0.4 mM PMSF, and 4 mM 
Na3VO4). The lysate was then centrifuged at 12,000 rpm for 3 minutes to 
remove the cell debris and the supernatant was collected. Whole-cell extract 
protein (ranging from 30-100 μg) was resolved on 12%, 10%, 15% SDS-
PAGE depending on the size of protein of interest, electro-transferred onto a 
nitrocellulose membrane, blocked (Blocking One, Nacalai USA, inc.) for 60 
min and blotted with antibodies against relevant proteins. Antibodies were 
prepared in either 1:100, 1:500 or 1:1000 dilutions in Bovine Serum Albumin 
(A9418 obtained from Sigma-Aldrich). The proteins were then detected by 
chemiluminescence (ECL; GE Healthcare, Little Chalfont, Buckinghamshire, 
UK) using a Gel Doc system. The densitometry analysis of the scanned blots 
was done using Image J software and the results are expressed as fold change 






2.2.11. RNA extraction and real-time PCR analysis 
Total RNA was extracted using the Trizol reagent (Life Technologies, 
Carlsbad, CA, USA), according to the manufacturer’s instructions. Reverse 
transcription was then carried out as described previously [161]. Briefly, for a 
50 μL reaction, 10 μL of RT product was mixed with 1x Taq-Man® Universal 
PCR Master mix, 2.5 μL of 20x TaqMan probes for Bcl-2, Bcl-XL and 
CyclinD1 respectively, 2.5 μL of 20x 18S RNA TaqMan probe as the 
endogenous control for each targeting gene, and topped up to 50 μL with 
sterile water. A negative control for RT, in which sterile water replaced the 
RNA template, was included. Another control, where RT mix was replaced 
with sterile water, was included to check for DNA contamination. Real-time 
PCR was done using 7500 Fast Real-Time PCR System (ABI PRISM 7500, 
Applied Biosystems, Foster City, CA, USA) with the following protocol; 50˚C 
for 2 minutes, 95˚C for 10 minutes, followed by 40 cycles of denaturing at 
95˚C for 15 seconds and extension at 60˚C for 1 minute. Results were 
analyzed using Sequence Detection Software version 1.3 provided by Applied 
Biosystems. Relative gene expression was obtained after normalization with 
endogenous human 18S RNA and determination of the difference in threshold 
cycle (Ct) between treated and untreated cells using 2-∆∆Ct method. Primers 
and probes for human Bcl-2, Bcl-XL, and CyclinD1 were purchased as kits 
from Applied Biosystems (Assays-on-Demand) as described previously [161]. 
 
2.2.12. Immunocytochemistry for E-cadherin localization  
AGS cells were seeded in Nunc Lab-Tek Chamber Slide (Thermo Fisher 
Scientific) in serum containing media and were left to attach overnight. On the 
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following day, the cells were washed with PBS. The cells were then fixed with 
cold acetone for 15 minutes. Upon fixing, the slide was placed for an hour in 
5% normal goat serum for blocking. The cells were then incubated with mouse 
monoclonal anti-human E-cadherin antibody (dilution, 1/100). After overnight 
incubation, the slides were washed which was followed by incubation with 
goat anti-mouse immunoglobulin G (IgG)-Alexa Fluor 594 (dilution, 1/100) 
for 1 hour and counterstained for nuclei with 4′,6-diamidino-2-phenylindole 
(DAPI; 0.5 μg/mL) for 15 minutes. At the end of the procedure, the slides 
were mounted with mounting medium (Sigma-Aldrich) and analyzed under a 
fluorescence microscope (Olympus DP 70). 
 
2.2.13 In-Silico analysis 
Please refer to Appendix-II 
 
2.2.14 Xenograft tumor model 
All procedures involving animals were approved by NUS Institutional Animal 
Care and Use Committee. Six week-old athymic nu/nu female mice (Animal 
Resource Centre, Australia) were used to develop a xenograft model. In the 
right flank of the mice, subcutaneous implantation was performed with SNU-5 
cells (3x 106 cells/100 μL saline). When tumor size reached 0.25 cm in 
diameter, the mice were randomized into the following four different 
treatment groups (n = 5/group) (a) untreated control (corn oil, 100 μL daily); 
(b) isorhamnetin alone (1 mg/kg bodyweight, suspended in corn oil, 
intraperitoneal injection thrice/week); (c) capecitabine alone (60 mg/kg 
bodyweight, suspended in corn oil,  twice weekly by gavage); and (d) 
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combination: isorhamnetin (1 mg/kg bodyweight, intraperitoneal injection, 
thrice/week) and capecitabine (60 mg/kg bodyweight,  twice weekly by 
gavage). Therapy was continued for 4 weeks, and the animals were euthanized 
1 week later and the final tumor volume was measured as V=4/3πr3, where r is 
the mean radius of the three dimensions (length, width, and depth). Tumor 
tissues obtained were fixed in formalin and embedded in paraffin for 
immunohistochemistry analysis.  
 
2.2.15. Immunohistochemical analysis of tumor tissues 
Solid tumors from control and isorhamnetin treated groups were fixed with 
10% phosphate buffered formalin, processed and embedded in paraffin. 
Sections were cut and treated with xylene, dehydrated in graded alcohol and 
finally hydrated in water. Antigen retrieval was performed by boiling the slide 
in 10 mM sodium citrate (pH 6.0) for 30 minutes. Immunohistochemistry was 
performed following manufacturer instructions (DAKO LSAB kit). Briefly, 
endogenous peroxidases were quenched with 3% hydrogen peroxide. Non-
specific binding was blocked by incubation in the blocking reagent in the 
LSAB kit according to the manufacturer’s instructions. Sections were 
incubated overnight with primary antibodies as follows: anti-PPARγ, anti-Bcl-
2, anti-CD31, anti-BMPR2, anti-COX-2 and anti-MMP-9 (each at 1:100 
dilutions). Slides were subsequently washed several times in Tris buffered 
saline with 0.1% Tween 20 and were incubated with biotinylated linker for 30 
min, followed by incubation with streptavidin conjugate provided in LSAB kit 
according to the manufacturer’s instructions. Immunoreactive species were 
detected using 3, 3-diaminobenzidine tetrahydrochloride (DAB) as a substrate. 
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Sections were counterstained with Gill’s hematoxylin and mounted under 
glass cover slips. Images were taken using an Olympus BX51 microscope 
(magnification, 20X). Positive cells (brown) were quantitated using the Image-
Pro plus 6.0 software package (Media Cybernetics, Inc.). 
 
2.2.16. Clinical Analysis  
Please refer to Appendix III 
 
2.2.17. Statistical analysis 
Statistical analysis was performed by student’s unpaired t test. One way 
ANOVA test was used when multiple groups had to be compared and 
Bonferroni method was used for post-test comparisons among the groups. In 
each case, *p values less than 0.05, **p<0.01, and ***p<0.001 were 
considered statistically significant. Bar graphs were plotted and statistical 





3.1. In silico analysis of anti-cancer effects of isorhamnetin 
Please refer to Appendix-II 
 
3.2. Anti-gastric cancer effects of isorhamnetin in vitro 
3.2.1. Isorhamnetin significantly suppresses the viability of diverse gastric 
cancer cells  
The most important characteristic of a cancer cell remains its ability to sustain 
proliferation. The cellular pathways that control proliferation in normal cells 
are perturbed in most cancers [162]. Tumor cells can proliferate using 
alternate strategies: autocrine signaling through which they might produce 
growth factors themselves and respond to it with their own cognate receptors 
or by manipulating normal cells in providing them with growth factors [163]. 
Thus, we first analyzed the effect of isorhamnetin on the viability of gastric 
cancer cells using a MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyltetrazolium bromide) assay, in which the reduction of MTT dye by 
active mitochondrial enzymes to formazan crystals is proportional to the 
amount of viable cells. Different gastric cancer cell lines including AGS, 
MKN45 and SNU-5 were employed for these experiments. The cells were 
exposed to 0, 5, 10, 25 and 50 µM concentrations of isorhamnetin for 0, 1, 2 
and 3 days and then subjected to MTT assay. The data obtained indicated that 
isorhamnetin can significantly inhibit the viability of all gastric cancer cells 








































Fig 3.2.1: Isorhamnetin inhibits the viability of gastric cancer cells. 
 
(A) AGS, (B) SNU-5 and (C) MKN45 cells were treated with 0, 10, 25 and 50 
µM of IH for 0, 1, 2 and 3 days. At the end of each time point, 20 µL of MTT 
solution was added and cells were incubated in the dark at 37°C for 4 hours. 
Following this, cells were lysed using freshly prepared lysis buffer as 
mentioned in “Materials and Methods”. Cell viability was measured at 570nm 
at the end of treatment using a Tecan plate reader (Durham, NC, USA). As 
seen in figure, viability of cells treated with isorhamnetin reduced significantly 
when compared to the control group (*p < 0.05) after treatment for indicated 
time points. Data expressed as mean ± standard deviation (SD) of two 






















































































































* * * 
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3.2.1.1. Isorhamnetin suppresses the viability of drug-resistant gastric 
cancer cells  
Cancer cells respond well to chemotherapeutic drugs in the initial stages of 
treatment.  However, with prolonged treatment, they begin to develop 
resistance to the first-line drugs [164]. Since the mechanisms of chemo-
resistance are unclear, combination therapy has been gaining attention recently 
as a means of chemo-sensitizing the cells to therapy [165]. Thus, we 
investigated the anti-proliferative effects of isorhamnetin in drug resistant 
gastric cancer cells. Two drug-resistant gastric cancer cells, namely, 
oxaliplatin-resistant NUGC3 and cisplatin-resistant AZ521 cells were treated 
with 0, 10, 25 and 50 µM of isorhamnetin for 0, 1, 2 and 3 days and then 
subjected to MTT assay. The data obtained indicated that isorhamnetin 
inhibits the viability of drug-resistant gastric cancer cells in a dose- and time-
dependent manner, as shown in Fig.3.2.1.1, thus providing evidence that 
isorhamnetin could sensitize drug resistant gastric cancer cells and could 









































Fig 3.2.1.1: Isorhamnetin inhibits the viability of drug-resistant gastric 
cancer cells. 
 
(A) Oxaliplatin resistant NUGC3 and (B) cisplatin resistant AZ521 cells were 
treated with 0, 10, 25 and 50 µM of IH for 0, 1, 2 and 3 days. At the end of 
each time point, 20 µL of MTT solution was added and cells were incubated in 
the dark at 37°C for 4 hours. Following this, cells were lysed using freshly 
prepared lysis buffer as mentioned in “Materials and Methods”. Cell viability 
was measured at 570nm at the end of treatment using a Tecan plate reader 
(Durham, NC, USA). As seen in figure, viability of cells treated with 
isorhamnetin reduced significantly when compared to the control group (*p < 
0.05) after treatment for indicated time points. Data expressed as mean ± 






















































































3.2.1.2. Isorhamnetin can suppress the viability of other tumor cell types 
To analyze the anti-proliferative effects of isorhamnetin on other tumor cell 
type(s) apart from gastric cancer, MTT assay was used to study the effect of 
isorhamnetin on the viability of breast, liver, prostate and head and neck 
cancer cells. Breast cancer (MDA-MB-231) cells, liver cancer (HepG2) cells, 
prostate cancer (DU145) cells and head and neck cancer (CAL27) cells were 
treated with 0, 10, 25 and 50 µM isorhamnetin for 0, 24, 48 and 72 hours and 
MTT assay was performed. The data clearly indicates that isorhamnetin can 
significantly reduce the viability of various tumor cell types, thereby 


















Fig 3.2.1.2: Isorhamnetin inhibits the viability of other tumor cell type(s).  
 
(A)  HepG2 and (B) MDA-MB-231 cells were treated with 0, 10, 25 and 50 
µM of isorhamnetin for 0, 1, 2 and 3 days. At the end of each time point, 20 
µL of MTT solution was added and cells were incubated in the dark at 37°C 
for 4 hours. Following this, cells were lysed using freshly prepared lysis buffer 
as mentioned in “Materials and Methods”. Cell viability was measured at 
570nm at the end of treatment using a Tecan plate reader (Durham, NC, USA). 
As seen in figure, viability of cells treated with isorhamnetin reduced 
significantly when compared to the control group (*p < 0.05) after treatment 
for indicated time points. Data expressed as mean ± standard deviation (SD) of 



























































































































Fig 3.2.1.2: Isorhamnetin inhibits the viability of other tumor cells 
(contd.).  
 
(C)  DU145 and (D) CAL27 cells were treated with 0, 10, 25 and 50 µM of 
isorhamnetin for 0, 1, 2 and 3 days. At the end of each time point, 20 µL of 
MTT solution was added and cells were incubated in the dark at 37°C for 4 
hours. Following this, cells were lysed using freshly prepared lysis buffer as 
mentioned in “Materials and Methods”. Cell viability was measured at 570nm 
at the end of treatment using a Tecan plate reader (Durham, NC, USA). As 
seen in figure, viability of cells treated with isorhamnetin reduced significantly 
when compared to the control group (*p < 0.05) after treatment for indicated 























































































3.2.1.3. Isorhamnetin does not significantly inhibit the viability of normal 
gastric epithelial cells  
It is well established that conventional chemotherapeutic agents deliver the 
drug to both normal and cancerous tissues, thus leading to undesirable adverse 
effects [166]. Several chemotherapeutic drugs currently used in treatment such 
as tamoxifen and capecitabine have been observed to induce undesired side-
effects on normal cells, such as atrophy and cardiomyopathy respectively 
[167, 168]. Thus, whether isorhamnetin could inhibit the viability of normal 
gastric epithelial cells was analyzed using MTT assay. HFE145 gastric 
epithelial cells were treated with 0, 20, 40 and 60 µM of isorhamnetin for 0, 1, 
2 and 3 days and then subjected to MTT assay. The data showed that 
isorhamnetin does not significantly inhibit the viability of normal gastric 
epithelial cells, thereby indicating its specificity towards tumor cells. 
 
Fig 3.2.1.3: Isorhamnetin does not affect the viability of normal 
gastric epithelial cells. 
 
HFE145 were treated with 0, 10, 25 and 50 µM of isorhamnetin for 0, 1, 2 
and 3 days and subjected to MTT assay. As observed, cell viability was 
not affected in the presence of various doses of isorhamnetin. Data 








































3.2.2. Isorhamnetin induces apoptosis in gastric cancer cells  
3.2.2.1. Isorhamnetin induces early apoptosis in gastric cancer cells 
During early apoptosis, the membrane phospholipid phosphatidylserine swiftly 
accumulates and moves from the cytoplasmic region to the extracellular 
surface [169]. This precedes other apoptotic processes such as loss of plasma 
membrane integrity, DNA fragmentation, and chromatin condensation. [159]. 
The loss of membrane symmetry can be detected by utilizing the binding 
properties of AnnexinV which is a 35-36 kDa, calcium dependent, 
phospholipid-binding protein with a high affinity for phospholipid 
phosphatidylserine (PS). It acts as an extrinsic membrane and is therefore an 
excellent tool to detect cell surface exposed to PS in vitro and in vivo and is 
considered to be a sensitive technique to detect early apoptosis [170]. The 
Annexin V staining assay was performed as described in “Materials and 
Methods”. The results showed that treatment of cells with isorhamnetin was 
able to increase the number of annexin V-positive cells substantially in a time-





































Fig 3.2.2.1: Isorhamnetin induces early apoptosis in gastric cancer cells. 
 
(A) AGS cells were treated with 25 µM of isorhamnetin for 0, 12, 24 and 48 
hours. Cells were then washed with PBS, stained with Annexin V and PI and 
analyzed using flow cytometry. Representative image from each treatment 
group is shown in the figure. (B) Percentage of apoptotic cells from two 
independent experiments was calculated and data obtained was plotted in bar 
graphs as mean ± standard deviation (SD). * indicates p value < 0.05 as 










































3.2.2.2. Isorhamnetin causes increased accumulation of gastric cancer 
cells in sub G1 phase 
Flow Cytometry (FCM) is an important technique for the accurate 
quantification of apoptosis which differentiates apoptotic cells from non-
apoptotic cells by DNA staining. Apoptosis is characterized by altered cell 
morphology in which plasma membrane excludes uptake of DNA-specific 
fluorochromes like propidium iodide (PI) [170]. The apoptotic cells with 
degraded DNA appear as cells with hypo diploid DNA content, seen as "sub-
G1" peaks on DNA histograms [171]. Initially, the cells were treated with 25 
µM isorhamnetin for 0, 12, 24, and 48 hours followed by fixing and staining 
as indicated in “Materials and Methods”. As evident from Fig. 3.2.2.2, our 
results showed that isorhamnetin can cause substantial increased accumulation 
of the cell population in the sub-G1 phase of the cell cycle in a time-dependent 


































Fig 3.2.2.2: Isorhamnetin induces sub-G1 accumulation in gastric cancer 
cells. 
 
(A) AGS cells were treated with 25 µM of isorhamnetin for 0, 12, 24 and 48 
hours. Cells were then washed with PBS, fixed with ethanol, stained with PI 
and further analyzed using flow cytometry. Representative image from each 
treatment group is shown in the figure. (B) Percentage of apoptotic cells from 
two independent experiments was calculated and data obtained was plotted in 
bar graphs as mean ± standard deviation (SD). * indicates p value < 0.05 as 
compared to control. 
  
48h 




Sub G1: 5.2% Sub G1: 8.8% 
Sub-G1 accumulation of cells



























3.2.2.3. Isorhamnetin induces PARP cleavage in gastric cancer cells  
Apoptosis is marked by changes in cellular morphology, as well as by 
cleavage of poly(ADP-ribose) polymerase (PARP) [172]. PARP cleavage 
aims at preventing the activation of PARP and hence targets at preserving 
cellular energy for certain ATP dependent steps of apoptosis [173]. It is 
subsequently cleaved into 89- and 24-kDa fragments that contain the active 
site and the DNA-binding domain of the enzyme, respectively, during drug-
induced apoptosis. We next analyzed if isorhamnetin could induce PARP 
cleavage in two different gastric cancer cells, namely AGS and SNU-16. Our 
results shows that there was a gradual decrease in the level of full length 
PARP and time-dependent increase in cleaved PARP in both the cell lines 
thereby indicating that isorhamnetin at 25 µM induces apoptosis in a time-
dependent manner in gastric cancer cells. 
 
Fig 3.2.2.3: Isorhamnetin increases PARP cleavage in gastric cancer cells. 
 
AGS cells were treated with 25 µM of isorhamnetin for 0, 6, 12, 24 and 48 
hours. Whole cell extract was prepared, separated on SDS-PAGE and 
subjected to western blot analysis to detect protein expression using PARP 
specific antibody. β-actin was used as a loading control. Densitometry analysis 
was performed to determine differences in fold change in protein bands 
between treated and control groups. 
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3.2.2.4. Isorhamnetin causes downregulation of expression of various 
oncogenic proteins in gastric cancer cells 
The BCL-2 protein family determines the commitment of cells to apoptosis 
and recent research has focused on the development of novel therapeutics that 
target these proteins [174]. Cyclin D1 is one of the most important proteins to 
regulate cell cycle, and related with the development of many cancers. 
Regulation of Cyclin D1 can induce G1 arrest and inhibit cell growth  [175].  
To analyze if isorhamnetin could also abrogate the expression of Bcl-2, Bcl-
xL and in gastric cancer cells, western blot analysis was performed. AGS and 
SNU-16 cells were treated with 25 µM for 0, 6, 12, 24 and 48 hours. Cells 
were then harvested and western blot analysis was done using specific 
antibodies to detect the various anti-apoptotic proteins. It was found that 
isorhamnetin can downregulate the expression of the above indicated proteins 





































Fig 3.2.2.4: Isorhamnetin inhibits the expression of Bcl-2, Bcl-XL and 
Cyclin D1 in gastric cancer cells. 
 
AGS and SNU-16 cells were treated with 25 µM of isorhamnetin for 0, 6, 12, 
24 and 48 hours. Whole cell extract was prepared, separated on SDS-PAGE 
and subjected to western blot analysis to detect protein expression using Bcl-2, 
Bcl-xL and Cyclin D1 specific antibodies. β-actin was used as a loading 
control. All experiments were done twice, and the best representative blot has 
been shown. Densitometry analysis was performed to determine differences in 





3.2.2.5. Isorhamnetin causes downregulation of expression of various 
oncogenic genes involved in the proliferation and survival of gastric 
cancer cells  
Our western blot analysis data showed that isorhamnetin could downregulate 
the expression of various anti-apoptotic/proliferative proteins and induce 
apoptosis in gastric cancer cells (Fig.3.2.2.5). Real time PCR was performed 
because it is currently the most sensitive method to determine the amount of a 
specific DNA in a complex biological sample [176]. To analyze if 
isorhamnetin could modulate the expression of proteins at the transcriptional 
level, gastric cancer cells were treated with 25 µM for 0, 2 and 4 hours and 
real time PCR analysis was done as described in “Materials and Methods”. 
The results clearly reveal that isorhamnetin also downregulated the expression 








































Fig 3.2.2.5: Isorhamnetin inhibits the transcription of anti-apoptotic and 
proliferative genes in gastric cancer cells. 
 
AGS cells were treated with 25 µM of isorhamnetin for 0, 2 and 4 hours. RNA 
samples were extracted. 1 µg portions of the respective RNA extracts were 
subjected to reverse transcription to generate corresponding cDNA. Real time 
PCR was performed to measure the relative quantities of mRNA. Each RT 
product was targeted against Bcl-2, Bcl-xL, and cyclin D1 TaqMan probes, 
with 18S RNA as endogenous control for measurement of equal loading of 
RNA samples. The results were analyzed using Sequence Detection Software 
version 1.3 provided by Applied Biosystems, * indicates p value < 0.05 as 


























































































































3.3. PPARγ as a possible molecular target of isorhamnetin 
3.3.1. Molecular docking of isorhamnetin with PPARγ 
Please refer to appendix 2  
3.3.2. Competitive binding of isorhamnetin with PPARγ 
An in vitro binding assay was performed to determine whether isorhamnetin 
could competitively bind to PPARγ and to determine its half maximum 
inhibitory concentration (IC50) [177]. Serial dilutions of isorhamnetin were 
prepared in a 384-well polypropylene assay plate. FluormoneTM Pan-PPAR 
Green, PPAR-γ-LBD, and Tb anti-GST Ab were then added to each sample 
well as described in the protocol. The results demonstrate that isorhamnetin 














Fig 3.3.2: Isorhamnetin effectively binds to PPARγ in a dose dependent 
manner.  
 
Serial dilutions of isorhamnetin and positive control GW1929 (both in 1% 
final DMSO concentration) were prepared in a white 384-well polypropylene 
assay plate. FluormoneTM Pan-PPAR Green, PPARγ-LBD, and Tb-anti-GST 
Ab were then added to each sample well as described in the protocol 
(LanthaScreen™ TR-FRET PPARγ Competitive Binding Assay kit). The 
assay mixture was incubated for 1 hour at room temperature prior to 
measuring the 520-nm/490-nm emission ratio of each well using a Tecan 
(Durham, NC, USA) plate reader. The error bars represent the S.D. of 
duplicate wells (n=2) and is the result of two independent experiments.  
PPAR competitive binding assay








































3.3.3. Effect of isorhamnetin on the PPARγ signaling cascade in gastric 
cancer cells 
3.3.3.1. Isorhamnetin activates PPARs in gastric cancer cells 
Based on the results of our previous experiments, we found that isorhamnetin 
could competitively bind to PPARγ. Therefore, we next analyzed if 
isorhamnetin could activate PPARγ in gastric cancer cells. AGS cells were co-
transfected with a chimeric receptor composed of PPARγ Ligand Binding 
Domain (LBD) fused to the GAL4 DNA Binding Domain (GAL4-mPPARγ 
LBD), along with a GAL4-responsive luciferase reporter construct, and renilla 
plasmid as internal control. In parallel experiments, cells were transfected with 
GAL4-mPPARδ LBD. Transcriptional activation of the respective PPAR 
isoforms by isorhamnetin was then assessed by luciferase assay as described 
in “Materials and Methods”. As shown in Fig.3.3.3.1, isorhamnetin was able 
to significantly increase the activity of two different PPAR isoforms namely 




































Fig 3.3.3.1: Effect of isorhamnetin on PPAR activity in gastric cancer cells 
 
AGS cells were transfected with either GAL4-PPARβ-LBD or GAL4-PPARγ-
LBD plasmids, along with GAL4-Luc and Renilla plasmids. The transfection 
was allowed for 4 hours following which cells were treated with 25 µM of 
isorhamnetin for 8 hours. After treatment, cells were lysed in reporter lysis 
buffer (Promega, USA) and the luciferase activity generated was immediately 
measured in the dark with a Tecan plate reader (Durham, NC, USA) and 
normalized against Renilla activity. The bars denote the percentage of PPAR 
activity compared to control. The plotted values represent the means ± SD of 
















































































3.3.3.2. Isorhamnetin induces significant transcriptional activation of 
endogenous PPARγ in gastric cancer cells 
Given that data from the initial screening reflected LBD transactivation of 
exogenous transfectants, we employed an additional luciferase system to study 
effect of isorhamnetin on endogenous PPARγ transcriptional activation. For 
this, AGS cells were transiently transfected with a luciferase-linked PPARγ 
reporter construct containing 3 X PPARγ response element (PPRE), or pTA-
luciferase (pTA-luc) empty vector before exposure to various doses of 
isorhamnetin. As shown in Fig. 3.3.3.2, isorhamnetin elicited robust dose-
dependent transcriptional activation of endogenous PPARγ receptor in AGS 
cells as demonstrated by 3xPPRE-tk-luc transfected cells, with negligible 
luciferase activity elicited in pTA-luc empty vector transfected control cells. 
Further kinetic studies revealed that isorhamnetin-induced activation of 
PPARγ was evident at the shortest time point tested (2 hours after treatment), 
and increased substantially in a time- and dose-dependent manner, reaching a 
peak at 8 hours after treatment. Similarly, the protein expression of PPAR-γ 







Fig 3.3.3.2: Isorhamnetin increases PPARγ activity and expression 
in a dose- dependent manner in gastric cancer cells. 
 
(A) AGS cells were transfected with pPPRE-tk-Luc and Renilla plasmid 
for 4 hours. The cells were then exposed to increasing doses of 
isorhamnetin. Following treatment, cells were lysed in reporter lysis 
buffer (Promega, USA) and luciferase activity was immediately 
measured with a Tecan plate reader (Durham, NC, USA) and normalized 
against Renilla activity. The data obtained as mean ± standard deviation 
(SD) of two independent experiments are expressed as percentages of 
the PPARγ activity relative to the control. * indicates p value < 0.05 as 
compared to control. (B) Gastric cancer cells were treated with 
increasing doses of isorhamnetin; 0, 5, 10, 25 and 50 µM. Whole cell 
extract was obtained, subjected to SDS PAGE analysis, transferred to a 
nitrocellulose membrane and analyzed using PPARγ specific antibody. 
Two independent experiments were performed and representative blot is 
shown. Densitometry analysis was performed to determine differences in 
fold change in protein bands between treated and control groups. 
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Fig 3.3.3.2: Isorhamnetin increases PPARγ activity and expression in 
a time- dependent manner in gastric cancer cells 
 
(C) Similar to the previous figure, AGS cells were seeded in a 24-well 
plate and allowed to adhere overnight. They were then transfected with 
pPPRE-tk-Luc and Renilla plasmid for 4 hours followed by exposure to 
25 µM of isorhamnetin for 0, 2, 4, 6 and 8 hours. Following treatment, 
cells were lysed in reporter lysis buffer (Promega, USA) and luciferase 
activity was immediately measured with a Tecan plate reader (Durham, 
NC, USA) and normalized against Renilla activity. The data obtained are 
mean ± standard deviation (SD) of two independent experiments. The 
plotted bars denote the percentages of the PPARγ activity relative to the 
control. * indicates p value < 0.05 as compared to control. (D) Gastric 
cancer cells were treated with 25 µM of isorhamnetin for 0, 2, 4, 6 and 8 
hours. Whole cell extract was obtained, subjected to SDS PAGE analysis, 
transferred to a nitrocellulose membrane and analyzed using PPARγ 
specific antibody. Two independent experiments were performed and 
representative blot is shown. Densitometry analysis was performed to 
determine differences in fold change in protein bands between treated 
and control groups. 
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3.3.3.3. Pharmacological blocker (GW9662) reverses isorhamnetin-
induced PPARγ activity in gastric cancer cells 
We next determined if isorhamnetin induced PPARγ transcriptional activation 
requires ligand binding to the receptor. To study this, we pre-incubated AGS 
cells with GW9662, a specific and irreversible antagonist of PPARγ, which 
acts by covalently modifying a cysteine residue in PPARγ ligand binding 
domain. Notably, it is known that this specific antagonist of PPARγ has 
negligible effect on the activity of PPARα and δ [178]. As illustrated in 
Fig.3.3.3.3, we observed that GW9662 could significantly attenuate ligand-
dependent PPARγ-activation induced by both isorhamnetin and an 







Fig 3.3.3.3: Isorhamnetin induced PPARγ activity could be partially 
reversed by GW9662, a pharmacological inhibitor of PPARγ. 
 
AGS gastric cancer cells were seeded onto a 24-well plate and allowed 
to adhere overnight. The cells were then transfected with GAL4-
PPARγ-LBD plasmids along with GAL4-Luc and Renilla plasmid for 4 
hours. Following transfection, the cells were exposed to 10 µM or 20 
µM GW9662 for 2 hours. Once exposed to the PPARγ antagonist, cells 
were now treated with 25 µM isorhamnetin (A) or 20 µM 15d-PGJ2 
(B), a PPARγ agonist, both for 18 hours. After the treatment, cells were 
lysed in reporter lysis buffer (Promega, USA) and luciferase activity 
was immediately measured with a Tecan plate reader (Durham, NC, 
USA) and normalized against Renilla activity. The data obtained are 
mean ± standard deviation (SD) of two independent experiments. The 
plotted bars denote the percentages of the PPARγ activity relative to the 




































































IH                -               -             +              + 
GW9662      -              +             -               + 
PGJ2           -              -              +             + 





3.3.3.4. DBD mutation of PPARγ partially reverses isorhamnetin 
mediated activation of PPARγ in gastric cancer cells  
Consequently, to investigate whether DNA-binding function of PPARγ was 
required for isorhamnetin induced PPARγ activation, we transfected AGS 
cells with either an empty vector or a DNA-binding defective form of PPARγ. 
This dominant negative form of PPARγ (PPARγ C126A/E127A) contains a double 
amino acid substitution in the DNA-binding domain (DBD), which annuls its 
ability to bind PPRE without affecting its potential for ligand binding [180]. 
This finding is consistent with previous studies which demonstrated that point 
mutations of these two critical amino acids in the first zinc finger of the DBD 
renders the receptor completely dysfunctional for transactivation [181].  
             Our data indicate that transfection with a dominant negative mutant 
PPARγ construct could partially reverse isorhamnetin induced activation of 
PPARγ (Fig.3.3.3.4 (A)). Also, we found that the dominant negative mutant 
could partially block isorhamnetin mediated apoptosis, as seen in Fig. 
3.3.3.4(B), by rescuing the expression of Bcl-2 and decreasing PARP 
cleavage. Taken together, our results show that isorhamnetin mediated anti-
apoptotic effects might be at least partially due to DNA binding function of 
PPARγ.   
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Fig 3.3.3.4: Transfection with dominant negative PPARγ partially 
reverses isorhamnetin-induced PPARγ activity.  
 
(A) AGS gastric cancer cells were first seeded on to a 24-well plate and 
allowed to adhere overnight. Upon checking the attachment of cells to 
the plate visually, they were transfected with PPARγ DN, along with 
pPPRE-tk-Luc and Renilla plasmids for 4 hours. Upon transfection, cells 
were allowed to grow for 48 hours and then treated with 25 µM of 
isorhamnetin for 18 hours. The data obtained are mean ± standard 
deviation (SD) of two independent experiments. The plotted bars denote 
the percentages of the PPARγ activity relative to the control. * indicates 
p value < 0.05 as compared to control. (B) The cells were transfected 
with PPARγ DN plasmids and treated with 25 µM of isorhamnetin for 
24 hours. Whole cell extract was obtained, subjected to SDS PAGE 
analysis and probed with PARP and Bcl-2 specific antibodies. Two 
independent experiments were performed and representative blot is 
shown. Densitometry analysis was performed to determine differences in 
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3.3.3.5. Selective role of isorhamnetin in activating PPARγ 
We have previously observed that isorhamnetin could also induce the 
activation of PPARβ in gastric cancer cells. Considering the similarity of 
different isoforms of PPAR, it was important to analyze whether this 
activation was a specific or non-specific phenomena. Therefore, we employed 
an established agonist of PPARβ, GW0472 and an antagonist, GSK0660, that 
can compete with an agonist at the cellular level [182], to examine the 
selective role of isorhamnetin in activating PPARγ.  Our data, as shown in Fig. 
3.3.3.5 (A), showed that GSK0660, was unable to reverse isorhamnetin-
induced PPARβ activity, whereas similar concentrations of GSK0660 could 
reverse the effect of GW0472 (Fig. 3.3.3.5 (B)), suggesting that the effect of 
IH on PPARβ activation was non-specific. Overall, through our experiments 
so far, we demonstrate for the first time that isorhamnetin exhibits anti-
proliferative and pro-apoptotic effects in gastric cancer cells and this effect is 

































Fig 3.3.3.5. Pharmacological inhibitor of PPARβ, GSK0660, could not 
block isorhamnetin-induced PPARγ activity. 
 
AGS gastric cancer cells were seeded on a 24-well plate and allowed to adhere 
overnight. They were later transfected with GAL4-PPARβ-LBD plasmids in 
combination with GAL4-Luc and Renilla plasmid for 4 hours. Following 
transfection, cells were allowed to grow for 48 hours after which they were 
pretreated with 50 µM GSK0660 for 4 hours followed by exposure to 25 µM 
isorhamnetin (A) or 10 µM GW0742 (B), a PPARβ agonist, both for 18 hours. 
Following treatment, cells were lysed in reporter lysis buffer (Promega, USA) 
and luciferase activity was immediately measured with a Tecan plate reader 
(Durham, NC, USA) and normalized against Renilla activity. The data 
obtained as mean ± standard deviation (SD) of two independent experiments 
are expressed as percentages of the PPARγ activity relative to the control.  
* indicates p value < 0.05 as compared to control. 
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IH                  -                    +                   + 
GSK0660      -                     -                   + 
GW0472       -                     +                    + 




3.4. Role of isorhamnetin in overcoming epithelial to mesenchymal 
transition  
3.4.1. Isorhamnetin inhibits CXCL12-induced migration of gastric cancer 
cells  
Clinical studies suggest that mortality rates of patients with advanced gastric 
cancer is high due to the complications caused by metastases of existing 
tumors [183]. Therefore, preventing metastasis is an effective approach for the 
successful treatment of gastric cancers. In recent years, numerous bioactive 
compounds obtained from natural sources have gained recognition as a source 
of development of novel agents that can considerably halt the progression of 
metastasis [184]. Cell migration is a complex cellular behavior that serves as 
an important step in the progression of metastasis in gastric cancer cells [185]. 
CXCL12 is a well characterized chemokine that can induce migration in a 
variety of cancer cells [186]. Therefore, we investigated the effect of 
isorhamnetin on the migratory potential of gastric cancer cells in the presence 
and absence of CXCL12 using the wound healing assay as shown in Fig. 
3.4.1(A).  
                            Our results showed that isorhamnetin could significantly 
inhibit the migration of gastric cancer cells. We also found that cancer cells 
migrated faster under the influence of CXCL12 and this effect was also 


















Fig 3.4.1: Isorhamnetin inhibits CXCL12 induced migration in gastric 
cancer cells. 
 
(A) AGS cells were seeded on a 6-well plate and allowed to grow until a 
uniform mono-layer was obtained. Following this, a wound was swiftly 
created on the plate using a pipette tip. The images of the wound were 
recorded under the microscope. Then, the cells were either treated with 25µM 
isorhamnetin and/or CXCL12 (100 ng/ml) for 8 hours. Gap difference was 
measured at the end of treatment and microscopic images were recorded. 
Representative images from each treatment group are shown. (B) The 
percentage of the gap difference between the treated and untreated groups was 
normalized and plotted in the form of bar charts. The values plotted are the 
means ± S.D. of two independent experiments. * indicates p value < 0.05 as 
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3.4.2. Isorhamnetin inhibits CXCL12-induced invasion of gastric cancer 
cells  
Tumor invasion consists of discrete biological processes in which tumor cells 
move from the primary neoplasm to the underlying stroma; this process 
involves the loss of adherence to other cells as well as cell adhesion to the 
extracellular matrix (ECM) [187]. Chemokines also contribute to invasion by 
inducing the infiltration of tumors by releasing proteases and other 
inflammatory molecules [188].  Recently, it has been reported that chemokine 
stromal cell-derived factor-1α (SDF-1α, also known as CXC-chemokine 
ligand 12, CXCL-12) and its receptor, CXC-chemokine receptor 4 (CXCR4), 
are involved in gastric cancer invasion and metastasis [189]. To analyze if 
isorhamnetin could inhibit the invasive capacity of gastric cancer cells, we 
used a BD biocoat tumor invasion system that consists of matrigel transwell 
chambers containing a light-tight polyethylene terephthalate membrane with 
8-µm diameter pores and coated with a reconstituted basement membrane gel. 
Upon treatment with isorhamnetin, there was a significant reduction in the 
number of cells that could invade the chamber, indicating that isorhamnetin 
could indeed inhibit the invasive property of gastric cancer cells. Moreover, 
isorhamnetin could also significantly reduce the number of cells that were 
induced to invade in the presence of CXCL12, confirming the inhibitory 










































Fig 3.4.2: Isorhamnetin inhibits CXCL12 induced invasion in gastric 
cancer cells. 
(A) A BD biocoat matrigel invasion chamber was used to study the invasion 
of gastric cancer cells. AGS gastric cancer cells were either treated with 25 
µM isorhamnetin and/or CXCL12 (100 ng/ml) for 8 hours. They were then 
fixed with 4% paraformaldehyde before staining with 0.5% crystal violet and 
pictures were recorded. Numbers of cells invading were counted at the end of 
treatment. Representative images from each treatment group are shown.  
(B) The percentage of the gap difference between the treated and untreated 
groups was normalized and plotted in the form of bar charts. The values 
plotted are the means ± S.D. of two independent experiments. * indicates p 






3.4.3. Effect of isorhamnetin on migration and invasion is partially 
reversed in the presence of pharmacological PPARγ specific inhibitor 
Previous studies have shown that ligand induced activation of PPARγ acts to 
inhibit the migration and invasion of cancer cells [190, 191]. A recent study 
also showed that both ectopic over-expression of PPARγ or its activation  by 
an agonist, rosiglitazone, could suppress the migration and invasion of the 
hepatocellular carcinoma cells in vitro and also inhibit the distant metastases 
from liver in an orthotopic hepatocellular carcinoma model in vivo [192]. To 
study if the inhibitory activity of isorhamnetin on migration of gastric cancer 
cells was via the PPARγ pathway, we employed a pharmacological blocker of 
the PPARγ, called GW9662 in our experiments, as mentioned previously. It is 
an irreversible, synthetic antagonist that can be utilized to distinguish PPARγ-
dependent and -independent effects of its ligands [193]. The effect of 
isorhamnetin on the migratory potential of gastric cancer cells was 
investigated using the wound healing assay. A ‘wound’ was created on a 
confluent mono-layer of cells, and the ability of cells to migrate was observed 
by measuring the gap difference before and after treatment. Cells were initially 
treated with GW9662 for 2 hours followed by exposure to 25 µM of 
isorhamnetin. The cells were then allowed to migrate for 8 hours. Our results 
as seen in Figs. 3.4.3(A) and 3.4.3(B) indicate that isorhamnetin significantly 
suppressed the migration of gastric cancer cells, and pretreatment with 
GW9662 reversed the anti-migratory effects of isorhamnetin. 




Similarly, the effect of isorhamnetin on the invasive capacity of gastric cancer 
cells was analyzed using a BD biocoat tumor invasion system. Gastric cancer 
cells were pre-treated with GW9662 for 2 hours before treatment with 
isorhamnetin for 8 hours. Our results show that isorhamnetin could inhibit the 
invasive capacity of gastric cancer cells and this effect was reversed in the 
presence of GW9662 as shown in Figs 3.4.3(C) and 3.4.3(D). Overall, the 
above experiments show that the anti-migratory and anti-invasive properties of 
isorhamnetin is primarily mediated through the PPARγ dependent pathway 
since the pretreatment with a specific PPARγ antagonist, GW9662, could 


























Fig 3.4.3: GW9662 reverses anti-migratory property of isorhamnetin in 
gastric cancer cells. 
 
 
(A) A wound was created with a pipette tip on 90% confluent AGS cells. 
Microscopic observation of the migration of the cells after pretreatment with 
GW9662 (20 µM for 2 hours), followed by incubation with isorhamnetin (25 
µM) for 8 hours was recorded. (B) The percentage of the gap difference 
between the treated and untreated groups of 3 replicates was normalized and 
plotted in the form of bar charts. The values plotted are the means ± S.D. of 

































Fig 3.4.3: GW9662 reverses anti- invasive property of isorhamnetin in 
gastric cancer cells. 
 
 
(C) The cell invasion assay was performed for evaluating the inhibitory effect 
of isorhamnetin on gastric cancer cell invasion. AGS cells were pretreated 
with GW9662 (20 µM for 2 hours) followed by incubation with isorhamnetin 
for 8 hours. They were then fixed with 4% paraformaldehyde after which they 
were stained with 0.5% crystal violet and pictures were recorded. (D) The 
percentage of the invaded cells of the treated group was normalized against the 
untreated group. The values are the means ± S.E. of two independent 





3.4.4. Transforming growth factor-β (TGF-β) treatment induces epithelial 
to mesenchymal transition in gastric epithelial and cancer cells 
Transforming growth factor-β signaling functions in several biological 
processes, including cell proliferation, differentiation and migration [194]. 
There is increasing evidence that TGF-β signaling promotes invasion and 
metastasis by induction of epithelial to mesenchymal transition (EMT) [143]. 
EMT is also characterized by breakdown of cell junctions and loss of 
epithelial phenotypes which leads to depolarization of cells, thus contributing 
to cancer progress [195]. Our initial aim was to test if TGF-β could induce 
EMT in two gastric cell lines; non-neoplastic gastric epithelial cell line 
HFE145 and gastric-epithelial-like cancer cell line, YCC1. Cells were treated 
with TGFβ (10 ng/ml) for 72 hours and microscopic images were captured 
after treating with crystal violet stain. As shown in Figs. 3.4.4(A) and 
3.4.4(C), TGF-β could induce phenotypic changes consistent with EMT in 
gastric cancer cells, including abnormal epithelial cell morphology, fibroblast-
like properties, and reduced intercellular adhesion [196].  
        The cells after treatment with TGF-β were also analyzed by western blot 
assay for various EMT marker proteins. Several EMT markers have been 
characterized in detail, including E-cadherin, Vimentin and gamma catenin. 
Reduced levels of E-cadherin have been extensively demonstrated in many 
cancers, in fact, E-cadherin-inactivating germline mutations have been 
reported to be a primary cause of hereditary diffuse gastric cancer (HDGC) 
[197]. Vimentin is considered a marker of mesenchymal differentiation and 
has been shown to induce invasive behavior in many epithelial carcinoma cell 
lines [198]. γ-catenin also known as plakoglobin, has been found to be 
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important in the normal epithelial tissue architecture. Reduced expression of γ-
catenin in human cancers has been closely associated with increased tumor 
progression and adverse clinical outcome [199]. Thus, considering the 
importance of the above indicated proteins in the EMT process, we analyzed if 
TGF-β could alter the expression of these proteins in both gastric epithelial 
and gastric cancer cells. As evident in the Figs. 3.4.4(B) and 3.4.4(D), TGF-β 
treatment resulted in a decreased expression of the epithelial markers E-
cadherin and γ-catenin and increased expression of the mesenchymal marker 
vimentin in both the cell lines. Considering that our above results indicated 
that TGF-β could induce EMT in the gastric epithelial and cancer cells, we 





































Fig 3.4.4: TGF-β treatment induces epithelial to mesenchymal transition 
in HFE145 gastric epithelial cells. 
 
(A) HFE145 cells were treated with 10 ng/ml of TGF-β for 72 hours. At the 
end of treatment, cells were stained with 0.5% crystal violet, washed with PBS 
and observed for morphological differences under the microscope, and 
photographs were recorded. (B) HFE145 cells were treated with 10 ng/ml of 
TGF-β for 72 hours. Whole cell extract was prepared, separated on SDS-
PAGE and subjected to western blot analysis to detect protein expression. β-
actin was used as a loading control. Data representative of at least two 
independent experiments have been shown. Densitometry analysis was 
performed to determine differences in fold change in protein bands between 
treated and control groups. 
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Fig 3.4.4: TGF-β treatment induces epithelial to mesenchymal transition 
in YCC1 gastric cancer cells. 
 
(C) YCC1 cells were treated with 10 ng/ml of TGF-β for 72 hours. At the end 
of treatment, cells were stained with 0.5% crystal violet, washed with PBS and 
observed for morphological differences under the microscope, and 
photographs were recorded.  (D) YCC1 cells were treated with 10ng/ml of 
TGF-β for 72 hours. Whole cell extract was prepared, separated on SDS-
PAGE and subjected to western blot analysis to detect protein expression. β-
actin was used as a loading control. Data representative of at least two 
independent experiments have been shown. Densitometry analysis was 
performed to determine differences in fold change in protein bands between 
treated and control groups. 
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3.4.5. Isorhamnetin reverses transforming growth factor-β (TGF-β) 
treatment induced epithelial to mesenchymal transition in gastric 
epithelial and cancer cells 
Cells that undergo EMT will switch from a polarized epithelial phenotype to a 
spindle-shaped, fibroblast-like mesenchymal phenotype [200]. To analyze if 
isorhamnetin treatment could reverse TGF-β induced EMT in gastric epithelial 
and cancer cells, we pre-treated the cells with isorhamnetin before exposing 
them to TGF-β (10 ng/ml) for 72 hours. Images of the cells captured under the 
microscope showed that isorhamnetin could substantially reverse the spindle-
shaped mesenchymal phenotype of cells to a polarized epithelial type.  
               During EMT, tumor cells lose expression of proteins, such as E-
cadherin, that promote cell-to-cell contact and acquire mesenchymal markers 
such as vimentin, and N-cadherin, which can drive cancer progression, 
invasion, and metastasis [201]. SNAIL is a transcription factor that represses 
epithelial genes by binding to E-box DNA sequences through their carboxy-
terminal zinc-finger domains, well-illustrated by its activity on the E-cadherin 
promoter [202]. To analyze if isorhamnetin treatment could reverse TGF-β 
induced EMT in gastric epithelial and cancer cells, we pre-treated the cells 
with isorhamnetin before exposing them to TGF-β (10 ng/ml) for 72 hours. 
The results indicated that increasing doses of isorhamnetin could reverse the 
TGF-β induced epithelial–mesenchymal transition. Treatment with TGFβ (as 
seen in the second lanes of Figs. 3.4.5(A) and 3.4.5(C)) induces a 
mesenchymal phenotype, as characterized by reduced expression of E-
cadherin (epithelial marker) and increase in the expression of mesenchymal 



















Fig 3.4.5: Isorhamnetin reverses TGF-β treatment-induced epithelial to 
mesenchymal transition in HFE145 gastric epithelial cells. 
 
(A) HFE145 cells were initially treated with 10 ng/ml of TGF-β before 
treatment with increasing doses of isorhamnetin for 72 hours. At the end of 
treatment, cells were exposed to 0.5% crystal violet, rinsed with PBS and 
observed for morphological differences under the microscope, and 
photographs were recorded. (B) HFE145 cells were pre-treated with 10ng/ml 
of TGF-β before treatment with increasing doses of isorhamnetin for 72 hours. 
Whole cell extract was prepared, separated on SDS-PAGE and subjected to 
western blot analysis to detect protein expression. β-actin was used as a 
loading control. Data representative of at least two independent experiments 
have been shown. Densitometry analysis was performed to determine 





































Fig 3.4.5: Isorhamnetin reverses TGF-β treatment-induced epithelial to 
mesenchymal transition in YCC1 gastric cancer cells. 
 
(C) YCC1 cancer cells were initially treated with 10 ng/ml of TGF-β before 
treatment with increasing doses of isorhamnetin for 72 hours. At the end of 
treatment, cells were were exposed to 0.5% crystal violet, rinsed with PBS and 
observed for morphological differences under the microscope, and 
photographs were recorded. (D) YCC1 cells were pre-treated with 10 ng/ml of 
TGF-β before treatment with increasing doses of isorhamnetin for 72 hours. 
Whole cell extract was prepared, separated on SDS-PAGE and subjected to 
western blot analysis to detect protein expression. β-actin was used as a 
loading control. Data representative of at least two independent experiments 
have been shown. Densitometry analysis was performed to determine 






3.4.6. Isorhamnetin induces relocalization of E-cadherin to the region of 
cell-cell adherent junction 
E-cadherin (Ecad), an important component of adherent junction in the 
epithelia acts as the master regulator of cell–cell adhesion and is known to 
function as a tumor suppressor in a majority of cancers due to its role in 
inhibiting cellular invasion [203]. The central role of Ecad in intercellular 
adhesion has been well studied and it has been shown that the loss of the 
protein can enhance gastric cancer progression in both mice and humans 
[204]. Since expression of Ecad is important in preventing tumor progression, 
we used an immunofluorescence staining method to analyze its expression in 
MKN28 gastric cancer cells. Using immunofluorescence, E-cadherin was 
shown to be expressed at a low level in MKN28 cells and to be localized 
mainly in the cytoplasm without significant membrane staining. Treatment 
with isorhamnetin for 24 hours showed a marked increase in E-cadherin. 
Interestingly, increased membranous staining was noted in the gastric cancer 
cells following treatment, suggesting relocalization of E-cadherin to the region 
of cell–cell adherent junctions, in addition to a substantial increase in its 
























Fig 3.4.6: Isorhamnetin up-regulates E-cadherin expression in gastric 
cancer cells. 
 
MKN28 cells were plated on a chamber slide and treated with isorhamnetin 
for 24 hours. The cells were then subjected to immunofluorescence analysis. 
They were incubated with mouse monoclonal E-cadherin antibody (1:100) 
followed by incubation with goat anti-mouse IgG-Alexa 594 (1:100) and 
counterstained for nuclei with Hoechst (50 ng/ml) for 5 min. Stained cells 
were mounted and analyzed under a fluorescence microscope. Green staining 
shows E-cadherin levels and blue staining shows the nucleus. The images 
were later merged using Olympus cell Sens Standard software. Representative 
image for each treatment group has been shown (n=2).   
 








3.4.7. Isorhamnetin reverses epithelial to mesenchymal transition in 
mesenchymal gastric cancer cells  
Flavonoids have been extensively studied for their role in reversing EMT in 
various cancers. For example, naringenin, a natural predominant flavanone, 
significantly inhibited the transcription of TGF-β1-induced Smad3, and 
reduced the binding probability of TGF-β1 to its specific receptor TβRII, thus 
suppressing the subsequent downstream signal transduction events [205]. 
Another study reported that some other flavonoids namely, rhamnetin and 
cirsiliol also showed increased expression of E-cadherin and decreased 
expression of vimentin and fibronectin, which consequently alleviated 
radiation-induced EMT both in in vitro and in vivo models [206]. Therefore, 
our next aim was to determine if isorhamnetin could reverse EMT in two 
different mesenchymal gastric cancer cells that were invasive in nature. Since 
EMT involves acquisition of mesenchymal markers such as vimentin by 
epithelial carcinoma cells and loss of epithelial cell adhesion molecules such 
as E-cadherin [207], we proceeded to investigate whether  isorhamnetin could 
reverse EMT by analyzing the expression levels of these proteins. AGS and 
MKN28 gastric cancer cells were treated with increasing doses of 
isorhamnetin and subjected to western blot analysis to study the expression of 
various epithelial and mesenchymal markers. E-cadherin and N-cadherin 
protein levels were observed to increase and decrease respectively in both the 
cell lines. Expression levels of vimentin in MKN28 (Fig. 3.4.7(B)) cells were 
also found to decrease, thereby indicating that isorhamnetin could modulate 
































Fig 3.4.7: Isorhamnetin reverses EMT in AGS and MKN28 gastric cancer 
cells. 
 
(A) AGS cells were treated with 0, 5, 10 and 25 µM of isorhamnetin for 24 
hours. Whole cell extracts were prepared, and lysates were subjected to 
western blot analysis using antibodies against E cadherin and N cadherin. β-
actin was used as a loading control. Data representative of two independent 
experiments are shown. (B) MKN28 cells were treated with 0, 5, 10 and 25 
µM of isorhamnetin for 24 hours. Whole cell extracts were prepared, and 
lysates were subjected to western blot analysis using antibodies against E 
cadherin, N cadherin and Vimentin proteins. β-actin was used as a loading 
control. Data representative of two independent experiments are shown. 
Densitometry analysis was performed to determine differences in fold change 
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3.4.8. Isorhamnetin inhibits expression of p-Smad3 in gastric cancer cells.  
TGF-β signaling can be Smad-mediated or non-Smad-mediated depending on 
the kind of cellular mechanism(s) involved [208]. The Smads are a group of 
intracellular proteins that transmit TGF-β ligand signals to the nucleus [209]. 
Activated TGF-β receptor phosphorylates a sub-class of Smads called 
receptor-activated Smads (R-Smads) such as Smad3; phosphorylated Smad3 
(p-Smad3) and then proceeds to bind to Smad-binding element (SBE) present 
in DNA sequences to regulate various TGF-β responsive genes [210]. Smad3 
phosphorylation as well as its downstream signaling has been shown to 
mediate the invasive and proliferative properties of cancer cells that are 
required for its progression [211].  
          Considering that p-Smad3 has been associated with a more invasive 
phenotype, and suggested to be a potential new prognostic marker of gastric 
carcinoma [212], we hypothesized that pharmacological inhibition of Smad3 
phosphorylation may help to repress gastric cancer progression. To analyze 
this aspect, gastric cancer AGS cells were treated with increasing doses of 
isorhamnetin for different time points and subjected to western blot analysis. 
As shown in Fig. 3.4.8(B), levels of p-Smad3 were found to decrease 
substantially both in a dose- and time- dependent manner upon isorhamnetin 
exposure thereby indicating that this flavonoid may block EMT through the 







































Fig 3.4.8: Isorhamnetin inhibits p-Smad3 expression in gastric cancer 
cells. 
 
(A) Transforming growth factor-β (TGF-β) superfamily signaling plays a 
critical role in a wide range of biological systems. Signaling is initiated with 
ligand-induced oligomerization of serine/threonine receptor kinases and 
phosphorylation of the cytoplasmic signaling molecules Smad2 and Smad3 for 
the TGF-β/activin pathway.  (B) AGS cells were treated with isorhamnetin in 
a dose- and time-dependent manner as indicated above. Whole cell extracts 
were obtained and subjected to western blot analysis using antibody against p-
Smad3. The membrane was later stripped and re-probed with Smad3 as a 
loading control. Data representative of two independent experiments are 
shown. Densitometry analysis was performed to determine differences in fold 
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3.5. BMPR2 is a possible target of PPARγ 
3.5.1. PPRE search database identifies BMPR2 as a target gene of PPARγ 
Bone morphogenetic proteins (BMPs) are members of the transforming 
growth factor-β family that bind to two types of serine-threonine kinase 
receptors, known as type I and type II receptors [213]. BMPs have been shown 
to favor angiogenesis by stimulating the secretion of pro-angiogenic growth 
factors, such as VEGF [214].  A recent study has also suggested that BMPR2 
could serve as a potential therapeutic target for renal cell carcinoma [215]. 
Upon understanding the angiogenic role of BMPR2, we first proceeded to 
determine if it was a putative target of the transcription factor, PPARγ.  
        PPARγ has a highly conserved DNA binding domain that recognizes 
specific DNA sequences known as Peroxisome Proliferator Response 
Elements (PPREs) [216]. Upon ligand binding, PPARγ translocates from 
cytoplasm to nucleus and forms a heterodimer with Retinoic-X-Receptor 
(RXR). PPAR/RXR complex then binds to PPRE located in the promoter 
region of PPAR target genes [217]. The PPRE region is composed of a Direct 
Repeat (DR) spaced by one nucleotide, DR1 or spaced by two nucleotides, 
DR2 [218]. We used a PPRE search database [219], which uses an in-silico 
approach, and identified that BMPR2 contains a putative PPRE in its promoter 
region. This led us to hypothesize that BMPR2 possibly contained a possible 






Fig 3.5.1: PPRE search database identifies BMPR2 as a possible target of 
PPARγ 
 
FASTA sequence of ‘Homo sapiens bone morphogenetic protein receptor, 
type II (serine/threonine kinase) (BMPR2), mRNA’ with NCBI Reference 
Sequence: NM_001204.6 was used as an input sequence in the PPRESearch 
database. The PPRE region is composed of a Direct Repeat (DR) spaced by 
one nucleotide, DR1 or spaced by two nucleotides, DR2. The database 
contains the PPRE repeats from the literature, shown to be experimentally 
validated through in vitro or in vivo binding assays. The PPRE isoform 
specificity, binding efficiency, pubmed id and their experimental validation 
assay type (in vitro or in vivo) for each PPRE (as reported in the literatures) 
are displayed in the output. The output we obtained shows that the database 
identifies BMPR2 to contain a putative PPRE in its promoter region with a 
high binding efficiency of 85% to PPARγ. Thus it could be a direct target of 




3.5.2. Knockdown of BMPR2 inhibits the migration and overexpression of 
BMPR2 restores the migratory potential of gastric cancer cells. 
Although the role of BMPs in bone formation has been well-studied, little is 
known about their influence on tumor cells. Recent studies indicate that BMPs 
are associated with increased migration and invasion of tumor cells. A recent 
report has shown that BMP-9 could induce EMT in hepatocellular carcinoma 
cells [220]. Yet another study suggested that inhibition of BMP-2 could 
suppress migration and invasion of lung cancer cells [221]. BMPR2 was also 
found to be highly expressed in two prostate cancer cell lines that had the 
ability to form osteoblastic lesions in vivo [158]. Clinical study data obtained 
from our collaborator’s lab also confirmed that BMPR2 had an inverse 
correlation to EMT in gastric cancer patient samples. Hence, we first 
proceeded to investigate if knockdown of BMPR2 could inhibit the migration 
of gastric cancer cells. Gastric cancer AGS cells were transfected with 
siBMPR2 and western blot analysis was performed to confirm the knockdown 
of BMPR2 as evidenced by Fig. 3.5.2(B). Then a wound healing assay was 
performed, and the gap difference was compared between cells transfected 
with control siRNA and those transfected with siBMPR2. As shown in Fig. 
3.5.2(A), cells with lower expression of BMPR2 migrated at a much slower 
rate than control cells.  
         Next we investigated if over-expression of BMPR2 protein could 
increase the migratory properties of gastric cancer cells. Gastric cancer AGS 
cells were transfected with BMPR2 and overexpression was confirmed using a 
western blot assay (Figs. 3.5.2(C) and 3.5.2(F)). A wound healing assay was 
performed and the comparison of the gap difference between control cells and 
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those with forced overexpression of BMPR2, as shown in Fig. 3.5.2(D), led us 
to conclude that cells with higher expression of BMPR2 could migrate faster 
than control cells.  
        Overall the results of the above experiments clearly indicate that BMPR2 
has an important role in modulating the migration of gastric cancer cells. With 
our previous experiments suggesting that BMPR2 might be a possible putative 
target of PPARγ, we next proceeded to analyze if a specific PPARγ agonist, 
troglitazone could modify the expression of BMPR2 and other EMT 



















Fig 3.5.2: Knockdown of BMPR2 inhibits the migration of gastric cancer 
cells. 
 
(A) AGS cells were seeded and transfected with either control siRNA or 
BMPR2 siRNA. 48 hours after transfection, a wound was created with a 
pipette tip and cells were allowed to migrate for 24 hours. Gap difference 
between control cells and BMPR2 knockdown cells was observed and images 
were recorded. (B) The percentage of the migratory cells of the treated group 
was normalized against the untreated group. The values are the means ± SD of 
three independent experiments. * indicates p value < 0.05 as compared to 
control. (C) Cells were later harvested, whole cell extract was obtained and 
probed for BMPR2 expression. β-actin was used as a loading control. Data 
representative of two independent experiments are shown. Densitometry 
analysis was performed to determine differences in fold change in protein 












Fig 3.5.2: Overexpression of BMPR2 induces the enhanced migration of 
gastric cancer cells.  
 
(D) AGS cells were seeded and BMPR2 was over-expressed. 48 hours after 
transfection, a wound was created with a pipette tip and cells were allowed to 
migrate for 24 hours. Gap difference between control cells and BMPR2 
knockdown cells was observed and images were recorded. (E) The percentage 
of the migratory cells of the treated group was normalized against the 
untreated group. The values are the means ± S.E. of three independent 
experiments. * indicates p value < 0.05 as compared to control. (F) Cells were 
later harvested, whole cell extract was obtained and probed for BMPR2 
expression. β-actin was used as a loading control. Data representative of two 
independent experiments are shown. Densitometry analysis was performed to 






3.5.3. Knockdown of BMPR2 reverses epithelial to mesenchymal 
transition of gastric cancer cells.  
Receptor knockdown studies have been routinely used in research to identify 
and validate the function of a specific protein [222, 223]. To understand the 
function of BMPR2 in gastric cancer cells, we next logically proceeded to 
knockdown the expression of BMPR2 using small interfering RNA (siRNA) 
and analyze the difference in the levels of EMT genes from the non-
transfected control cells. A recent study showed that siRNA-mediated 
knockdown of BMPR2 in Smad4 negative cells in colorectal cancer cells 
could lead to a decrease in their invasive ability [224]. Therefore we next 
elucidated the exact role of BMPR2 in EMT process of gastric cancer cells 
through a RNA interference methodology.  
     AGS cells were transfected with the most efficient concentration of siRNA 
and harvested for western blot analysis after 48 hours.  The results as shown in 
Fig. 3.5.3, revealed that knockdown of BMPR2 could reverse EMT, as shown 
by the up-regulation in the expression of E-cadherin and down-regulation in 
the expression of N-cadherin thereby suggesting that BMPR2 has an important 
























Fig 3.5.3: Knockdown of BMPR2 reverses epithelial to mesenchymal 
transition of gastric cancer cells. 
 
AGS cells were seeded and transfected with either control siRNA or BMPR2 
siRNA. 48 hours after transfection, cells were harvested and whole cell extract 
was obtained. Post western blot analysis, the expression of BMPR2, E 
cadherin and N cadherin was studied. β-actin was used as a loading control. 
Data representative of two independent experiments are shown. Densitometry 
analysis was performed to determine differences in fold change in protein 
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3.5.4. Ligand induced activation of PPARγ reverses EMT in gastric 
cancer cells 
PPARγ agonists have been well studied for their ability to suppress 
proliferation, inhibit metastasis and induce apoptosis [225]. However, their 
role as inhibitors of epithelial to mesenchymal transition has not been explored 
extensively. A research group recently showed that curcumin, a polyphenolic 
natural compound, could counteract TGF-β1-induced EMT in renal tubular 
epithelial cells via ERK- and PPARγ- dependent pathway [226]. Yet another 
study reported that troglitazone, a synthetic PPARγ agonist, could 
significantly prevent TGFβ-2 induced epithelial-mesenchymal transition of 
retinal pigment epithelium cells [227]. Hence, we proceeded to analyze next 
whether troglitazone (structure shown in Fig. 3.5.4(A)) and isorhamnetin 
could modulate the expression of BMPR2 and other epithelial to mesenchymal 
transition markers in gastric cancer cells.  
        Gastric cancer AGS cells were treated with increasing doses of 
troglitazone and the expression level of BMPR2 and N-cadherin proteins was 
determined using western blot analysis. The results as shown in Fig. 3.5.4(B), 
showed that troglitazone could down-regulate the levels of BMPR2. It could 
also increase the expression of E-cadherin in a time-dependent manner. 
Isorhamnetin could also decrease BMPR2 levels in a dose-dependent manner. 
Overall, our experiments so far have indicated that ligand induced activation 
of PPARγ could inhibit EMT in gastric cancer cells. We next proceeded to 
analyze if this observed inhibitory effect was indeed primarily mediated 










Fig 3.5.4: Ligand induced activation of PPARγ reverses EMT in gastric 
cancer cells. 
 
(A) Chemical structure of troglitazone. (B) AGS cells were seeded and treated 
with increasing doses of troglitazone (10, 20 and 40 µM). Cells were then 
harvested, whole cell lysate was prepared and western blot analysis was done 
to detect the expression of BMPR2, E cadherin and N cadherin. β-actin was 
used as a loading control. Data representative of two independent experiments 
are shown. (C) AGS cells were treated with 0, 10, 25 and 50 µM of 
isorhamnetin for 24 hours. Cells were then harvested, whole cell lysate was 
prepared and western blot analysis was done to detect the expression of 
BMPR2 protein. Experiment was performed twice, and representative image is 
shown. Densitometry analysis was performed to determine differences in fold 
change in protein bands between treated and control groups. 
A 




3.5.5. Inhibition of EMT by isorhamnetin is partially reversed by a 
dominant negative form of PPARγ  
As explained earlier, PPARγ dominant negative mutant is a DNA-binding 
defective form of PPARγ that suppresses its ability to bind to PPRE without 
affecting its ligand binding capacity. These mutants have been regularly used 
by researchers to understand if a specific mechanism is directly mediated 
through a PPARγ dependent pathway [228, 229]. Therefore, we next 
proceeded to investigate if PPARγ dominant negative mutant could inhibit the 
ability of isorhamnetin to modulate BMPR2 and markers of EMT in gastric 
cancer cells.  
      Gastric cancer AGS cells were treated with isorhamnetin for 24 hours after 
transfection with empty pCMX vector or pCMX DN mutant followed by 
western blot analysis to study the expression of EMT proteins. As shown in 
Fig.3.5.5, treatment of the cells with isorhamnetin could down-regulate the 
expression of BMPR2 protein. This was reverted back to its normal levels 
when a mutant was used. Isorhamnetin substantially increased the levels of E 
cadherin but this effect was less evident in the presence of a dominant 
negative mutant. Isorhamnetin also decreased the expression of N cadherin, 
but this effect seems to be consistent even in the presence of a mutant 
receptor. In other words, abolishing PPARγ activity did not affect the 
expression of N cadherin. Overall, using a PPARγ dominant negative mutant, 
we demonstrate that inhibition of EMT by isorhamnetin is at least partially 

























Fig 3.5.5: Inhibition of EMT by isorhamnetin is partially reversed by a 
dominant negative form of PPARγ. 
 
AGS cells were seeded and transfected with either empty pCMX vector or 
pCMX dominant negative mutant. 48 hours post transfection, the cells were 
harvested, whole cell lysate was prepared and western blot analysis was done 
to detect the expression of BMPR2 and E cadherin. β-actin was used as a 
loading control. Data representative of two independent experiments are 
shown. Densitometry analysis was performed to determine differences in fold 
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3.5.6. Isorhamnetin does not modulate the expression of BMP4, the ligand 
of BMPR2  
BMPs are secreted growth factors, belonging to the TGF-β superfamily, that 
exert their effects by binding to the BMP receptors. BMP4 and BMP7 have 
been found to be strongly expressed in primary and metastatic melanomas and 
contribute to their enhanced migration and invasion during tumor development 
[230]. A few studies have also suggested a possible link between PPARγ 
activation and down-regulation of BMP4 protein. For example, a report 
showed that increase in PPARγ signaling altered the expression of Shh, FGF, 
Wnt, and BMP4 genes that are important for epithelial–mesenchymal crosstalk 
during the early lung development process [231].  
    To elucidate whether the observed inhibitory effects of isorhamnetin on 
EMT were specifically mediated via BMPR2, we next analyzed if treatment of 
gastric cancer cells with isorhamnetin could modulate the expression of 
BMP4, ligand of BMPR2. Two mesenchymal gastric cancer cells, AGS and 
AZ521 were treated with increasing concentrations of isorhamnetin and the 
expression of BMP4 protein was studied by western blot analysis. Our results, 
as shown in Fig.3.5.6, indicate that isorhamnetin could not substantially affect 
the expression of BMP4 protein in gastric cancer cells thereby confirming its 

























Fig 3.5.6: Isorhamnetin does not affect the expression of BMP4 in gastric 
cancer cells. 
 
(A) AGS cells were treated with 0, 5, 10, 25 and 50 µM of isorhamnetin for 24 
hours. Whole cell extracts were prepared, and lysates were subjected to 
western blot analysis using antibodies against BMP4. β-actin was used as a 
loading control. Data representative of two independent experiments are 
shown. (B) AZ521 cells were treated with 5, 10, 25 and 50 µM of 
isorhamnetin for 24 hours. Whole cell extracts were prepared, and lysates 
were subjected to western blot analysis using antibodies against BMP4. β-
actin was used as a loading control. Data representative of two independent 
experiments are shown. Densitometry analysis was performed to determine 
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3.6. Identification of isorhamnetin as a novel chemo-sensitizing agent in 
gastric cancer 
3.6.1. Isorhamnetin enhances the cytotoxic effects of chemotherapeutic 
agents against gastric cancer cell lines  
The use of a combination regimen of chemo-therapeutic drugs has been found 
to be superior in comparison to the effect of these agents used alone in the 
treatment of cancer. Research suggests that combined chemo-therapy 
improves local tumor control, reduces the rate of recurrence in patients 
without systemic disease, and eliminates residual primary tumor cells as a 
source of potential subsequent metastases [232]. Recent studies show that 
natural compounds could also work effectively in combination with existing 
anticancer therapies to combat cancer [233]. Our group has published a study 
in which we found that gamma-tocotrienol, a novel Vitamin E analogue, could 
chemo-sensitize gastric cancer cells to capecitabine in a xenograft mouse 
model [234]. Hence, our first aim was to analyze if isorhamnetin could act in 
combination with chemo-therapeutic drugs to inhibit gastric cancer cell 
viability. Therefore, we examined using the MTT assay whether isorhamnetin 
at a suboptimal concentration could enhance the cytotoxic effects of 
chemotherapeutic agents commonly employed for gastric cancer treatment. 
Growth inhibition rate was obtained and calculated as the percentage of dead 
cells versus control. Following a 24 hour treatment, it was found that 
isorhamnetin could significantly enhance the cytotoxicity of two 




Our results showed that 10 µM of isorhamnetin could indeed significantly 
enhance the cytotoxic effects of 5-fluorouracil and capecitabine in gastric 






Fig 3.6.1: Isorhamnetin inhibits growth of gastric cancer cells in 
combination with chemotherapeutic agents.  
 
AGS gastric cancer cells (5x103) were seeded in a 96 well plate and treated 
either alone with 10 µM of isorhamnetin, 60 nM of 5-fluorouracil, 2.5 µM of 
cisplatin and 10 µM of capecitabine or in a combination of each of the agents 
with 10 µM of isorhamnetin to investigate if it could enhance their cytotoxic 
effects. At the end of treatment, 20 µL of MTT solution was added and cells 
were incubated in the dark at 37°C for 4 hours. Cell viability was measured at 
570nm at the end of treatment using a Tecan plate reader (Durham, NC, 
USA).Values are means ± SD of three independent experiments. * indicates p 
value < 0.05 as compared to control.  
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3.6.2. Isorhamnetin augments the apoptotic effects of capecitabine in 
gastric cancer cells in-vitro 
Capecitabine, an oral fluoropyrimidine precursor, was first approved in 2001 
for the treatment of metastatic colon cancer and has been used interchangeably 
with parenteral 5-fluorouracil in the treatment of upper gastrointestinal (GI) 
cancers [29]. Clinical trials show that outcome of patients receiving 
capecitabine is significantly better as compared to patients receiving 5-
fluorouracil [235]. However, despite its efficacy, capecitabine has been linked 
to increased chemo-resistance in cancers. A study stated that a significant 
proportion of locally advanced rectal cancer patients do not respond well to 
standard treatment with fluoropyrimidines (capecitabine or 5-fluorouracil), 
requiring radical surgical resection, accompanied by a  significant chance of 
relapse [236]. Yet another study showed that clinical refractoriness to 
nucleoside analogs, such as capecitabine, could be one of the main reasons 
underlying the extremely poor prognostic state of pancreatic cancer [237].  
          Therefore, we next proceeded to investigate if isorhamnetin at a sub-
optimal dose could potentiate the effects of capecitabine and overcome 
chemo-resistance in gastric cancer cells. We employed an esterase staining 
assay (live/dead assay) to confirm whether isorhamnetin can significantly 
augment the apoptosis induced by capecitabine. As shown in Fig. 3.6.2, the 
sub-optimal doses of isorhamnetin (10 M) or capecitabine (10 M) had little 
effect on apoptosis alone but produced substantial enhancement of apoptosis 
when used in combination. Taken together, these data suggest that 



























Fig 3.6.2: Isorhamnetin enhances the apoptotic effects of capecitabine in 
gastric cancer cells. 
 
SNU-5, SNU-16 and MKN-45 cells were treated either alone with 10 µM of 
isorhamnetin or 10 µM of capecitabine, or a combination of both to assess the 
capacity of these agents to induce apoptosis either alone or in combination. 
Cells were treated with LIVE/DEAD® Cell Viability Assay reagents (Life 
technologies), mounted on a slide and analyzed under a fluorescence 
microscope as described under “Materials and Methods”. Two independent 
experiments were performed and bar graph representing the mean + standard 
deviation is shown. The combination of both agents could significantly 
enhance apoptosis in three different gastric cancer cells. * indicates p value < 
0.05 as compared to control. 
* 









































3.6.3. Isorhamnetin enhances the inhibition of tumor growth induced by 
capecitabine in vivo 
In-vivo evaluation of any anti-cancer drug is a critical step in predicting its 
efficacy before it can be tested under clinical settings. A variety of tumor 
systems are available, however, scientists typically employ subcutaneously 
growing tumor models because they can be predictive when performed under 
controlled conditions [238]. Therefore, we developed a human gastric cancer 
xenograft model in nude mouse by implanting gastric cancer SNU-5 cells. 
Thereafter, we analyzed the therapeutic potential of isorhamnetin and 
capecitabine either alone, or in combination, on the growth of subcutaneously 
implanted human gastric cancer cells in nude mice. The schematic 
representation of the experimental protocol is depicted in Fig. 3.6.3(A). SNU-
5 cells were implanted subcutaneously in the right flank of nude mice.  When 
tumors reached 0.25 cm in diameter after a week, the mice were randomized 
into 4 groups and exposed to chemo-therapeutic agents as per the experimental 
protocol. The treatment was continued for 4 weeks, and animals were 
sacrificed after 5 weeks. Interestingly, we noted that isorhamnetin or 
capecitabine alone when given at 1 mg/kg body weight produced a dramatic 
decrease in tumor volume as compared to control group (Fig, 3.6.3[D]). In the 
combination treatment group, significant reduction in tumor volume was 
observed when compared to control group or capecitabine alone group (p < 










Fig 3.6.3: Isorhamnetin enhances the anti-tumor effect of capecitabine in 
gastric cancer xenograft mouse model. 
 
(A) A schematic representation of the in vivo experimental protocol. Group 1 
mice were injected with vehicle control (corn oil), Group 2 mice were given 
isorhamnetin (1 mg/kg body weight) through an intra-peritoneal injection, 
while Group 3 mice were given capecitabine (60 mg/kg body weight) through 
oral administration. Group 4 consisted of mice given a combination of 
isorhamnetin and capecitabine. (B) SNU-5 cells were injected subcutaneously 
into the right flank region of each nude mouse. When tumor reached 0.25 cm 
in diameter, the mice were randomized into 4 treatment groups, each n=5. 
After 5 weeks of treatment, mice were sacrificed and tumor volume was 
measured. Representative pictures of tumors isolated from different treatment 








Fig 3.6.3: Isorhamnetin enhances the inhibitory effect of capecitabine in 
gastric cancer in-vivo (contd.). 
 
(C) Therapeutic regimen of isorhamnetin and capecitabine either alone, or in 
combination, was administered to nude mice (previously injected with gastric 
cancer cells) for 4 weeks, and the animals were euthanized on the final day of the 
experimental protocol. The final tumor volume was measured as V=4/3πr3, where 
r is the mean radius of the three dimensions (length, width, and depth). Data are 
represented as mean + SD (n=5). (D) Data are represented as mean + SD (n=5). 





3.6.4. Isorhamnetin in combination with capecitabine inhibits expression 
of proliferative and angiogenic biomarkers in gastric cancer tissues 
Ki-67 is a protein that is found to be absent in quiescent cells (G0) and 
universally expressed in proliferating cells [239]. It has been shown to be of 
prognostic influence in non-small cell lung cancer with a high index pointing 
toward poor prognosis [240]. A recent study found that the Ki-67 expression 
rate was 70.6% in the well- and medium-differentiated gastric cancer, 90% in 
the poorly differentiated gastric cancer and 90.9% in the non-infiltrated tissues 
suggesting that its expression is closely related to the clinical pathological 
characteristics of gastric cancer [241]. On the contrary, CD31 expression is 
related to neovascularization and may be associated with the clinical course of 
the cervical tumor [242]. Prior preclinical studies on gastric cancer have 
focused on analyzing the expression of CD31 to understand the anti-cancer 
and anti-angiogenic effects of various pharmacological drugs [243, 244].  
            Considering the clinical importance of Ki-67 in proliferation, and 
CD31 in angiogenesis of gastric cancer, we proceeded to determine if 
isorhamnetin in combination with capecitabine could modulate their 
expression in gastric tumor tissues.  Fig. 3.6.4(A) shows that isorhamnetin and 
capecitabine alone downregulated the expression of Ki-67 in gastric tumor 
tissues and the combination of the two was most effective (p<0.001). 
Similarly, when examined for CD31, we found that both agents significantly 
reduced the CD31 expression (Fig. 3.6.4(B)) as compared to control group and 









Fig 3.6.4: Isorhamnetin in combination with capecitabine inhibits the 
expression of Ki-67 and CD-31 in a gastric cancer xenograft model.  
 
(A) Tumor tissues obtained after 35 days of treatment were subjected to 
immunohistochemistry analysis using Ki-67 specific antibody as described under 
“Materials and Methods” section. Images were taken using an Olympus BX51 
microscope (magnification ×40). Representative image for each group is shown 
above. Positive cells (brown) were quantitated using the Image-Pro plus 6.0 
software package (Media Cybernetics, Inc.). (B) Tumor tissues were subjected to 
immunohistochemistry using CD31 specific antibodies as described under 
“Materials and Methods” section. Images were taken using an Olympus BX51 
microscope (magnification × 40). Representative image for each group is shown 
above. Positive cells (brown) were quantitated using the Image-Pro plus 6.0 
software package (Media Cybernetics, Inc.). *** indicates p<0.001 as compared 








































































































3.6.5. Isorhamnetin negatively regulates the expression of various 
oncogenic proteins involved in gastric cancer progression in tumor tissues 
We observed using our in-vitro assays that isorhamnetin could modulate the 
expressions of various oncogenic proteins involved in survival, angiogenesis 
and metastasis. Therefore, we next proceeded to analyze if isorhamnetin alone 
or in combination with capecitabine could affect the expression of VEGF, 
COX-2 and MMP-9 in gastric tumor tissues. Vascular endothelial growth 
factor (VEGF) is one of the most commonly studied angiogenic molecule and 
is considered as an important biomarker in gastric cancer progression [245]. It 
has been reported as one the most potent and specific promoter of tumor 
angiogenesis and correlates with poor prognosis in gastric cancer patients 
[246]. Matrix metalloproteinases (MMPs) are enzymes that play an important 
role in tumor growth, invasion and metastasis [247]. Cyclooxygenase-2 
(COX-2) has also been reported to be involved in gastric cancer invasion and 
its inhibition can suppress both angiogenesis and tumor growth [248]. Hence, 
we used an immunohistochemistry assay to analyze if isorhamnetin alone 
and/or in combination with capecitabine could affect the expression of these 
oncogenic proteins in tumor tissues. As shown in Fig.3.6.5, the expression of 
all these proteins was significantly downregulated in gastric tumor samples 
treated with isorhamnetin in combination with capecitabine. The 





























Fig 3.6.5: Isorhamnetin alone or in combination with capecitabine 
modulates the expression of various genes involved in gastric cancer 
progression in tumor tissues 
 
Tumor tissues obtained after 35 days of treatment with either corn oil, 
isorhamnetin alone, capecitabine alone and a combination of isorhamnetin and 
capecitabine were subjected to immunohistochemistry analysis using VEGF, 
COX-2 and MMP-9 specific antibodies as described under “Materials and 
Methods” section. Images were taken using an Olympus BX51 microscope 
(magnification ×40). Representative image for each group is shown above. 
Positive cells (brown) were quantified using the Image-Pro plus 6.0 software 
package (Media Cybernetics, Inc.).  
MMP-9 
VEGF 
IH+ CAP CAP IH Vehicle control 
COX-2 
82 ± 2% 37 ± 1% 29 ± 2% 11 ± 4% 
79 ± 4% 33 ± 2% 31 ± 3% 12 ± 3% 
97 ± 2% 40 ± 3% 38 ± 2% 16 ± 2% 
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3.6.6. Isorhamnetin modulates the expression of BMPR2 and PPARγ in 
gastric tumor tissues 
As mentioned earlier, BMP contribution in cancer is being extensively studied, 
considering the fact that they possess both, pro- and anti-tumorigenic activities 
in different cancers [249, 250]. Since our preliminary in-vitro data showed that 
isorhamnetin could increase the activation of PPARγ and inhibit the 
expression of BMPR2, we next proceeded to investigate if similar effects 
could be observed under in-vivo settings.  
            Hence, we used an immunohistochemistry assay to analyze if 
isorhamnetin alone and/or in combination with capecitabine could affect the 
expression of these two proteins in gastric tumor tissues. As shown in 
Fig.3.6.6, isorhamnetin could significantly downregulate the expression of 
BMPR2 and upregulate the expression of PPARγ in tumor tissues, thereby 
reemphasizing our central hypothesis that anticancer effects of isorhamnetin 

























Fig 3.6.6: Isorhamnetin alone or in combination with capecitabine 
modulates the expression of BMPR2 and PPARγ in gastric tissues 
 
Tumor tissues obtained after 35 days of treatment with corn oil, isorhamnetin, 
capecitabine or a combination of isorhamnetin and capecitabine, were subjected 
to immunohistochemistry analysis using BMPR2 and PPARγ specific antibodies 
as described under “Materials and Methods” section. Images were taken using an 
Olympus BX51 microscope (magnification ×40). Representative image for each 
group is shown above. Positive cells (brown) were quantified using the Image-Pro 
plus 6.0 software package (Media Cybernetics, Inc.).  
BMPR2 
92 ± 2% 50 ± 7% 40 ± 9% 20 ± 6% 
PPAR 
36 ± 3% 57 ± 4% 30 ± 3% 85 ± 5% 




4.1. Gastric cancer incidence and treatment options 
Gastric cancer remains the fifth leading cancer worldwide in incidence, and it 
is the second leading cause of cancer-related mortality. It arises primarily 
through a cascade of events; namely non-atrophic gastritis, atrophic gastritis, 
gastric intestinal metaplasia (IM), gastric dysplasia, and, ultimately, gastric 
cancer [251]. According to the Singapore Cancer Registry Interim Report, 
gastric cancer is the 5th commonest cancer in males and 7th commonest 
cancer in females in Singapore. The exact mechanism(s) underlying this fatal 
disease is/are still being studied, but several prior studies have linked it to 
Helicobacter pylori infection [252].  
           Surgical and endoscopic resection remains to be the standard care for 
treatment of localized cancers of the gastro-intestinal tract while 
chemotherapy is primarily used in the patients with advanced tumors [253]. 
Chemotherapeutic treatments are primarily based on platinum and 
fluoropyrimidine combinations, or in three-drug regimens including taxanes or 
anthracyclines [254]. Palliative chemotherapy prolongs survival and improves 
cancer-related symptoms in patients with primary metastatic disease [255]. 
However, despite the availability of novel targeted therapies, gastric cancer 
remains significantly incurable with patients either developing chemo-
resistance or relapsing after an initial response [256]. Moreover, majority of 
the drugs currently in use have severe side-effects and/or dose limiting toxicity 
[257], thereby indicating an urgent need to identify novel pharmacological 
agents that could mitigate the drawbacks associated with existing drugs.  
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4.2.Anti-cancer activity of natural compounds 
The role of natural products as potent anti-cancer agents has been widely 
studied by various research groups.  Till today, the interest in herbal 
compounds has been immense, with various groups engaged in active research 
to identify anticancer efficacy of plant derived agents. A recently published 
review article showed that natural compounds may also exhibit their 
anticancer effects by overcoming apoptotic resistance in pancreatic cancer 
cells [258].  These compounds have been extensively studied, owing to their 
effectiveness in treatment, relatively lower cost, and minimal side effects. 
Also, many synthetic drugs have the basic structure of natural compounds as 
their scaffold, and the quality of these leads have been found to better and 
often more biologically active as compared to their synthetic counterparts 
[259].  
     Natural products have also been shown to be highly effective in anti-ulcer 
treatment owing to their gastro-protective properties [260]. Flavonoids, in 
particular, have been extensively studied for their anti-oxidant and anti-
inflammatory actions on various metabolic diseases as well as cancer [261]. 
Isorhamnetin is one such flavonoid that has been gaining attention for its 
chemo-preventive activity, as evident by the increasing research interest on 




4.3. Isorhamnetin: A novel natural agent 
4.3.1. Investigating the cytotoxic effects of isorhamnetin against tumor 
cells 
The major hurdles faced in the development of an anti-cancer agent drug are 
primarily related to the complexity of tumor cells and their associated 
microenvironment, as well as their similarity to the normal cells [264]. Since 
the ‘hallmarks of cancer’ defined by the renowned scientist Dr. Robert 
Weinberg include the ability of cancer cells to sustain proliferative signaling, 
evade cell death and induce metastasis [6], we aimed to identify a 
pharmacological agent that possessed the ability to overcome these pivotal 
characteristics of tumor cells. The most fundamental trait of a cancer cell 
remains to be its ability to sustain proliferation, as opposed to normal cells, 
that have a tightly controlled mechanism(s) to maintain homeostasis inside the 
cell. Thus, our initial experiments focused on assessing the cytotoxic effect of 
isorhamnetin on various gastric cancer cells.  
             We observed a significant decrease in the viability of various gastric 
cancer cells in vitro after treatment with isorhamnetin. Lauren’s classification 
divides gastric carcinoma into diffuse and intestinal subtypes and thus we 
selected three different gastric cancer cell lines; SNU5 is a diffuse type cell 
line whereas AGS and MKN45 are intestinal type cancer cell lines [265]. As 
shown in the results (Fig. 3.2.1), we observed that isorhamnetin could 
significantly inhibit the cytotoxicity of different gastric cancer cells in a dose- 
and time-dependent manner. These results are concurrent with other studies 
which show that isorhamnetin can act as a potent anti-proliferative agent 
against skin and colorectal cancer cells [136, 139].  
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             Current treatment for advanced gastric cancer consists of a 
combination of cytotoxic drugs; cisplatin as well as targeted agents such as 
trastuzumab had superior effects in randomized trials when compared to other 
agents like oxaliplatin, oral fluoropyrimidines and irinotecan that exhibited 
relatively less toxic results [266]. However, treatment with these agents is 
characterized by resistance, which is both acquired and intrinsic. This 
resistance could be caused by numerous cellular adaptations, including 
inactivation by glutathione and other anti-oxidants, as well as a rise in the 
levels of DNA repair or DNA tolerance [267]. Cancer drug resistance, 
therefore, is a complicated process and overcoming it is an important trait of 
an effective drug [268]. Our results indicated that isorhamnetin treatment 
could also significantly inhibit the viability of oxaliplatin-resistant NUGC3 
cells and cisplatin-resistant AZ521 cells as seen in Fig. 3.2.1.1, thereby 
indicating that isorhamnetin could be used as a potent chemosensitizer of 
tumor cells.  
             When a drug is successful in one clinical setting, it encourages 
clinicians to further explore its efficacy for the therapy of other cancers as 
well. A classic example is imatinib, a tyrosine kinase inhibitor, which was 
initially discovered for the treatment of chronic myeloid leukemia and was 
then employed for the treatment of  other tumors such as gastrointestinal 
stromal tumors and epithelial ovarian cancer [269]. Isorhamnetin was 
therefore tested on other tumor cell types as well, and as shown in Fig. 3.2.1.2, 
it could significantly inhibit the viability of MDA-MB-231 breast cancer cells, 
HepG2 liver cancer cells, DU145 prostate cancer cells and CAL27 head and 
neck cancer cells. These finding suggests that anticancer effects of 
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isorhamnetin are not restricted only to gastric cancer cells, but applicable on 
other solid tumors as well. The similarity of cancer and normal cells in the 
body, as described above, deem it important to analyze if the observed 
anticancer action of a drug is specific to tumor cells and it does not 
significantly affect the viability of non-transformed cells. As evident from Fig. 
3.2.1.3, our results showed that isorhamnetin did not significantly alter the 
viability of HFE145 normal gastric epithelial cells when treated at various 
doses and time points.  
                Overall, the results of the above experiments indicate the potential 
effectiveness of isorhamnetin as an anti-proliferative agent and its specificity 
towards cancer cells. Also, the ability of isorhamnetin to sensitize drug 
resistant gastric cancer cells shows that it could potentially be used as a 




4.3.2. Isorhamnetin induces apoptosis in gastric cancer cells 
Apoptosis is a tightly programmed cell death that eliminates unwanted cells 
and maintains the healthy balance between cell survival and death. Cancer 
cells, however, evade apoptosis allowing them to survive over their intended 
lifespan, thereby accumulating genetic alterations that ‘deregulate cell 
proliferation, interfere with differentiation, promote angiogenesis, and increase 
invasiveness during tumor progression’ [270]. Considering the importance of 
apoptosis as a regulatory mechanism to limit cancer progression, we 
performed the next set of experiments to analyze the potential role of 
isorhamnetin as a pro-apoptotic agent. The induction of apoptosis can be 
assessed by the accumulation of the cells in the Sub G1 fraction of the cell 
cycle. Our results, as seen in Fig. 3.2.2.2, showed that isorhamnetin could 
increase the accumulation of gastric cancer cells in the Sub G1 phase in a 
time-dependent manner. We also utilized an annexin V assay to detect the loss 
of membrane symmetry, a phenomenon that occurs during apoptosis. 
Treatment of cells with isorhamnetin was able to increase the number of 
annexin V-positive cells in a time-dependent manner, thus indicating induction 
of early apoptosis (Fig. 3.2.2.1). The results were concurrent with a recent 
study which showed that isorhamnetin could induce cell death and facilitate 
cell cycle progression to G0/G1 phase in colorectal cancer cells [136].  
       Activation of poly (ADP-ribose) polymerase (PARP) has been studied as 
an important hallmark of apoptosis because of its involvement in various 
cellular and molecular processes, such as cell survival and DNA repair [271]. 
A study evaluated the effect of isorhamnetin on human lymphoblastoid cells 
and found that it could increase PARP cleavage and induce apoptosis in the 
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cells [272].  Our study showed similar results, with isorhamnetin inducing 
PARP cleavage in two different gastric cancer cells in a time-dependent 
manner (Fig. 3.2.2.3).  Along the same line, we also analyzed whether 
isorhamnetin modulated the expression of anti-apoptotic and anti-proliferative 
genes, such as Bcl-2, Bcl-xL and Cyclin D1.  Our experiments confirmed that 
the flavonol could down-regulate the expression of these proteins in a time-
dependent manner in two different gastric cancer cell lines (Fig. 3.2.2.4). This 
finding is in agreement with another study that indicated that isorhamnetin 
could modulate various oncogenic genes in favor of apoptosis in esophageal 
squamous carcinoma cells after 72 hours of exposure [273]. Isorhamnetin 
treatment also significantly down regulated the expression of various anti-
apoptotic genes namely, Bcl-2, and Bcl-xL (Fig.3.2.2.5) thereby indicating that 
it can act as potent pro-apoptotic agent against cancer cells.  
 
 
4.3.3. Potential molecular mechanism(s) of action of isorhamnetin 
Our initial attempts to identify the potential molecular mechanism of 
anticancer actions of isorhamnetin led us to identify that it could bind to an 
important transcription factor called PPARγ. It is a nuclear receptor that is 
involved in the regulation of inflammation and in the processes of cellular 
proliferation, differentiation, and apoptosis [274]. In most cases, 
pharmacological agents with PPARγ-activating ability are found to be direct 
ligands of the receptor; physical binding to the receptor thus appears to be the 
most common mechanism for receptor activation. Our first step in this context, 
the computational docking of isorhamnetin with the crystal structure of 
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PPARγ, showed promising results as seen in Fig. S3.3.1. The complex of 
isorhamentin and PPARγ had interaction energy of -27.73 kcal/mol. The 
flavonol was found to have interactions with 5 polar residues and 9 non-polar 
residues in the receptor. Among these interactions, Cys 285 and Ser 289 were 
previously found to be essential for PPARγ ligand binding and activity [275, 
276]. (Please refer to Appendix 2: data kindly provided by collaborator Dr. 
Chun Wei Yap, NUS School of Pharmacy). 
           We further validated the computational docking data by using the 
LanthaScreen time-resolved fluorescence resonance energy transfer (TR-
FRET) PPARγ competitive binding assay (Life Technologies, Carlsbad, CA). 
This assay quantitatively determines the ability of novel test compounds to 
bind to purified hPPARγ LBD in vitro. The assay showed that isorhamnetin 
could indeed bind competitively to PPARγ with an IC50 of 12.18 µM. The 
fact that competitive binding is purely a bio-chemical and not cell-based assay 
might explain the lower IC50 value we obtained as compared to that observed 
previously in cell viability assays.  
       We utilized a combination of experimental techniques to ascertain PPARγ 
activation as the primary mode of action of isorhamnetin. As described earlier, 
PPARs are a family of transcription factors that have three sub-types; PPARα, 
PPARδ/β and PPARγ. Structure based studies have revealed that the three 
PPARs share a similar structure but differ in their spectrum of activity [277]. 
PPARα has not been explored extensively in cancer; only a few studies exist 
that indicate its role as an anti-cancer target upon activation [190, 278]. 
However, the role of PPARδ/β and PPARγ as potential anti-cancer targets has 
been well analyzed. Overexpression and/or ligand activation of PPAR-β/δ has 
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been shown to inhibit relative breast cancer tumorigenicity [279] and reduce 
invasion in pancreatic cancer [280]. It was thus important for us to investigate 
if isorhamnetin could activate PPARδ/β and PPARγ subtypes in gastric cancer 
cells. Therefore, cells were transfected with either GAL4-mPPARγ LBD or 
GAL4-mPPARδ LBD and analyzed for isorhamnetin induced activity through 
a luciferase based reporter assay. As seen in Fig. 3.3.3.1, isorhamnetin could 
activate both PPARδ/β and PPARγ subtypes in gastric cancer cells. 
Interestingly, though isorhamnetin could activate PPARδ/β, pre-treatment with 
a specific PPARδ/β pharmacological blocker, GSK0660 could not reverse its 
effect. However, activation of PPARδ/β through a specific PPARδ/β agonist, 
GW0472 could be reversed by pre-treatment with GSK0660 as shown in Fig. 
3.3.3.5. These results suggest that the activation of PPARδ/β by isorhamnetin 
is not mediated through its direct binding to PPARδ/β, but possibly through a 
non-specific mechanism. However, the mild activation observed could be 
beneficial, given the numerous anti-cancer effects of PPARδ/β.  
          Consequently, we employed a 3xPPRE-tk-luc reporter plasmid to 
further characterize the effect of isorhamnetin on PPARγ signal transduction 
cascade in gastric cancer cells (Fig. 3.3.3.2). Our results revealed that 
isorhamnetin-induced PPARγ activation was evident as early as 2 hours after 
treatment, and increased substantially in a time- and dose-dependent manner, 
reaching a peak after 8 hours of treatment. We also observed an up-regulation 
of PPARγ protein expression upon treatment with isorhamnetin in a time- and 
dose- dependent manner, a phenomenon commonly observed in cells being 
directly exposed to PPARγ agonists [281, 282] that enhances its anti-cancer 
effects. A large cohort study also showed that PPARγ expression is 
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independently associated with better prognosis in colorectal cancer [283] 
suggesting that over-expression of PPARγ could positively regulate its 
biological actions.  
             Our next aim was to determine if isorhamnetin-induced activation of 
PPARγ required direct ligand binding to the receptor. To study this, we 
utilized GW9662, a specific antagonist of PPARγ that has negligible effect on 
the activity of PPARα and δ. We observed that GW9662 could significantly 
attenuate ligand-dependent PPARγ-activation induced by both isorhamnetin 
and an endogenous ligand, 15d-PGJ2 that can activate PPAR response 
elements as shown in Fig. 3.3.3.3. Also, an Annexin-V staining analysis after 
pre-treatment of cells with GW9662 showed a partial reversal of isorhamnetin 
induced apoptosis as shown in Fig. 3.3.3.5. This further indicated that the 
observed apoptotic effects of isorhamnetin could be partially mediated through 
the direct binding and activation of PPARγ.  
        Like other steroid hormone nuclear receptors, PPARγ contains a ligand-
binding domain (LBD); a trans-activating domain (activation function 2), 
which, when activated by a ligand, changes its conformation to induce 
transcriptional activation; and a DNA-binding domain, which interacts with 
specific PPAR response elements (PPRE) that is found in the promoter region 
of PPAR-regulated target genes [284]. Therefore, we used a dominant 
negative form of PPARγ (PPARγ C126A/E127A) to confirm whether DNA-
binding functional domain of PPARγ was also required for the observed 
effects of isorhamnetin. Our results as shown in Fig. 3.3.3.4 indicate that 
isorhamnetin induced activation of PPARγ was substantially reversed in the 
presence of the mutant receptor. Also, isorhamnetin induced apoptosis was 
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attenuated in the presence of a dominant negative receptor, as evidenced by 
partial reversal of PARP cleavage and no change in the expression of Bcl-2 
(Fig. 3.3.3.4 (B)). These findings indicate that the DNA-binding function of 
PPARγ is necessary for isorhamnetin induced apoptosis; in other words, we 
show that the anticancer effects of isorhamnetin are at least partially mediated 
through PPARγ activation.  
           Upon literature review, we further noted that the key amino acid, 
Tyr473, required for the binding of full agonists to human PPARγ [275] is not 
required for isorhamnetin induced PPARγ activity. We also observed that the 
capacity of isorhamnetin to activate PPARγ is approx. 50% lesser as compared 
to 15d-PGJ2 [285], an established endogenous ligand of PPARγ. Moreover, 
use of a PPARγ antagonist and dominant-negative mutant could only partially 
rescue the effects of isorhamnetin, suggesting that it could be functioning as a 
‘partial PPARγ agonist’.  
With the failure of current PPARγ agonists, thiazolidinediones in the 
clinic, our finding that isorhamnetin could be a partial PPARγ agonist comes 
as a ‘blessing in disguise’. It has been suggested that the adverse effects of 
PPARγ activators could be mitigated through use of partial PPARγ agonists, 
which can maintain the efficacy of full PPARγ agonists while lacking their 
typical side effects, such as edema and weight gain [286]. Whether 
isorhamnetin could efficiently function as a partial PPARγ agonist under in 
vivo settings, without inducing the side effects normally observed while using 
full PPARγ agonists, was evaluated in the later part of the project.  
           Research has shown that PPARγ heterodimerizes with the retinoid X 
receptor (RXR), another nuclear receptor activated by its own ligand 
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(purportedly 9 cis-retinoic acid), to initiate transcription [284]. However, in 
our study, experiments were focused solely on PPARγ without any artificial 
modulation of its binding partner RXR in the heterodimer, in order to analyze 
the specificity of isorhamnetin towards the PPAR receptor. Nevertheless, 
given the involvement of RXR in classical PPARγ-mediated transcriptional 
regulation of target genes, further studies are required to gain a detailed 
understanding of the involvement of RXR in the observed significant increase 
in PPARγ activity induced by isorhamnetin.  
 
 
4.3.4. Isorhamnetin overcomes epithelial to mesenchymal transition in 
gastric cancer cells  
Epithelial to mesenchymal transition is described as a process in which cells 
lose epithelial characteristics and gain mesenchymal ones, accompanied by a 
loss of cell-cell cohesiveness and enhanced migratory capacity [146]. 
Increasing evidence(s) suggest that gastric tumor cells harness epithelial to 
mesenchymal transition to increase their migratory and invasive ability [287]. 
The stromal-derived factor-1 (SDF-1)/CXCR4 axis also known as the 
CXCL12/CXCR4 axis is deregulated in multiple human cancers and blockade 
of this axis has been shown to inhibit pancreatic cell migration and invasion 
in-vitro [288]. Therefore, we investigated if isorhamnetin could inhibit the 
migratory and invasive capacity of gastric cancer cells, in the presence and 
absence of CXCL12. As evidenced by Fig. 3.4.1 and Fig. 3.4.2, isorhamnetin 
could significantly inhibit the migration and invasion of gastric cancer cells. 
We also found that CXCL12 induced gastric cancer cell migration and 
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invasion and this effect was significantly reduced upon treatment with 
isorhamnetin.  
        Several prior studies have indicated that activation of an endogenous or 
ectopically expressed PPARγ can inhibit cancer cell migration and invasion 
[289]. To elucidate if isorhamnetin mediated inhibition of gastric cancer cell 
migration and invasion was mediated through the PPARγ pathway, we pre-
treated the cells with a pharmacological inhibitor of PPARγ, GW9662 [290], 
followed by exposure of  isorhamnetin. Our results show that isorhamnetin 
could inhibit the invasive capacity of gastric cancer cells and this effect was 
partially reversed in the presence of GW9662 as shown in Figs. 3.4.3(C) and 
3.4.3(D). Overall, we found that isorhamnetin is an effective anti-migratory 
and anti-invasive agent, and this effect is mediated at least in part through the 
modulation of PPARγ activation pathway.   
               Induction of EMT by TGF-β represents one of the key cell biological 
processes that mediate pro-tumorigenic actions. However, it appears to have a 
paradoxical role in tumor environment. TGF-β usually performs the role of a 
tumor suppressor in normal cells, and in early-stage carcinomas possibly via 
its ability to induce cell cycle arrest and apoptosis. Interestingly, as 
carcinomas begin to evolve and ultimately acquire metastatic characteristics, 
TGF-β begins to function as an oncogene that stimulates carcinoma growth, 
invasion, and metastasis [291]. Therefore, we next investigated if TGF-β could 
induce EMT in two gastric cell lines; non-neoplastic gastric mucosa cell line 
HFE145 and gastric-epithelial-like cancer cell line, YCC1. We found that 
treatment with TGF-β could induce fibroblast-like properties in cells, and 
convert them from an epithelial state to a mesenchymal state, as observed 
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through the modulation of various EMT regulated proteins like E-cadherin, 
vimentin and gamma-catenin [292]. This induced EMT was found to be 
reversed upon treatment with isorhamnetin, as observed by the increase in the 
expression of E-cadherin, and decrease in the expression levels of N-cadherin, 
and Vimentin proteins. Moreover, our results indicated that isorhamnetin 
could increase the expression of E-cadherin and induce its relocalization to the 
region of cell-cell adherent junction as shown in Fig. 3.4.6. We also found that 
isorhamnetin could reverse EMT in mesenchymal gastric cancer cells, AGS 
and MKN28, which are highly invasive in nature. Research groups have 
previously reported the potential of several dietary flavonoids to act as anti-
metastatic agents against various cancers [293], however, ours is the first to 
prove the effectiveness of isorhamnetin as a potent anti-invasive/ant-metastatic 
agent in gastric cancer. 
            TGF-β activates a type I TGF-β receptor (TβRI) which phosphorylates 
Smad3, a receptor-activated Smad protein. In advanced cancer, this TGF-
β/SMAD pathway can act as an oncogenic factor driving tumor cell invasion 
and metastasis, and is considered to be a therapeutic target [294]. Our results 
show that isorhamnetin could inhibit the expression of p-Smad3 in a time- and 
dose-dependent manner, thereby indicating that it may negatively regulate 
EMT in gastric cancer through inhibition of Smad3 mediated TGF-β signaling.  
             Bone morphogenetic proteins (BMP) are members of the TGF-β 
family, that mediate a highly conserved signal transduction cascade through 
the type-I and type-II serine/threonine kinase receptors. Though BMP 
signaling has largely been regarded as tumor suppressive, studies are emerging 
that portray their role as tumor-promoters. An important report published 
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recently showed that systemic inhibition of the BMP pathway (which is active 
in both the tumor cells and the surrounding tumor microenvironment) may 
lead to anti-metastatic functions in mammary cancer [249]. Clinical data 
kindly provided by our collaborator, Prof. Jean Paul Thiery (Appendix 3), 
provided us with hindsight that BMPR2 might have a direct correlation with 
EMT. We also deciphered through the patient data that higher expression of 
BMPR2 showed poor prognosis in gastric cancer. Therefore, we hypothesized 
that BMPR2 could play a major role in gastric tumor progression.  Hence we 
proceeded to analyze whether isorhmanetin could down-regulate the 
expression of BMPR2 and if this down-regulation was also mediated through 
the PPARγ activation pathway.  
             Investigation of the molecular mechanism of PPARγ has clearly 
indicated that upon activation by a ligand, it bound to a DNA response 
element, PPRE (peroxisome proliferator response element), which is a DR-1 
direct repeat of the consensus sequence TGACCT × TGACCT [295]. Even 
though majority of studies have focused purely on PPRE sites containing the 
DR1 region, our group has shown previously that genes containing a DR2 
(direct repeats separated by two nucleotides) sequence could also be a 
potential PPARγ target [219]. We therefore used a PPRE search database, with 
BMPR2 gene sequence as the input and search criteria to include DR2 regions, 
as shown in Fig. S3.5.1, and found that bone morphogenetic protein receptor2 
could possibly be a direct target of PPARγ, since it contained a putative PPRE 
region. 
          Along this line, we first proceeded to investigate the role of BMPR2 in 
epithelial to mesenchymal transition. We proceeded to either knockdown or 
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over-express BMPR2 to observe its effects. Knockdown of BMPR2 
significantly inhibited the migration of gastric cancer cells, while over-
expression of BMPR2 could increase the number of migratory cells as shown 
in Fig. 3.5.2. We also found that knockdown of BMPR2 could at least partially 
reverse EMT in gastric cancer cells, observed by the up-regulation of E-
cadherin and down-regulation of N-cadherin, seen in Fig. 3.5.3. Taken 
together with the clinical data, we show that BMPR2 has an important role in 
promoting migration and epithelial-to-mesenchymal transition in gastric 
cancer. 
     Upon understanding the role of BMPR2 in promoting gastric cancer 
progression, we next examined if its tumor-promoting role was PPARγ 
dependent. Hence our first step was to analyze if troglitazone, known to be a 
potent PPARγ agonist, and isorhamnetin, which we have shown to be a partial 
PPARγ agonist, could modulate the expression of BMPR2 in gastric cancer 
cells. As observed in Fig. 3.5.4, our results showed that both the therapeutic 
agents could indeed down-regulate the expression of BMPR2 as well as other 
EMT regulated genes. We also found that use of a PPARγ dominant negative 
mutant could partially reverse the inhibitory effects of isorhamnetin on 
BMPR2 and EMT, as shown in Fig. 3.5.5, confirming that this inhibition of 
BMPR2 expression could be partially mediated through the DNA binding 
function of PPARγ.  Review of existing literature indicated us that only 12 
studies so far have investigated the role of PPARγ in EMT. Ours is therefore 
possibly the first study to report that activation of PPARγ could modulate 




              TGFβ can function as either a tumor-suppressor or tumor-promoter 
and thereby regulate a variety of cellular processes in cancer [296]. The 
biological effects of TGF-β family members are highly contextual; their 
behavior may vary according to the local environments and stage of disease. 
In our study, we show that BMPs promote gastric cancer progression, and 
inhibition of BMPR2 can partially reverse this phenomenon. However, 
considering the role of various other factors, such as hetero-dimerization of 
BMPR2 with BMPR1 and involvement of Smad1/5/8 pathway in BMP 
signaling, further studies are required to completely validate its role in gastric 
cancer. Nevertheless, the finding that BMPR2 promotes EMT, and that its 
effect may be modulated by PPARγ, is an important step in the identification 
of potential targets in cancer therapy.  
 
 
4.3.5. Isorhamnetin enhances the inhibition of tumor growth induced by 
capecitabine in a gastric cancer xenograft model  
Scientists have become increasingly dependent on mouse models to provide a 
clearer, pre-clinical evaluation of their test compound, based on the opinion 
that use of cell lines alone in a study might not be entirely successful. This is 
because cell lines are believed to be constantly changing in culture, rarely 
retaining the tumor heterogeneity present in the primary cancer and/or 
containing the components of the classical tumor environment [297]. 
Xenograft models are the most popular pre-clinical models for evaluating the 
anti-cancer activity of anti-neoplastic agents. Transplanted tumors were 
initially rejected in mice, which was later improved by the use of nude mice 
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with absence of thymus, which had significantly reduced capacity to reject 
‘foreign’ tissues [298].  
        We therefore developed a human gastric cancer xenograft model in 
athymic nude mice using SNU-5 cells to examine the effects of isorhamnetin 
under preclinical settings. These cells are highly invasive in nature [244], and 
our group has successfully implanted them in nude mice previously to develop 
a gastric cancer tumor model [234].  Capecitabine (Xeloda, Roche) is an orally 
administered fluoropyrimidine drug that is enzymatically converted to 5-
flurouracil following absorption from the gastrointestinal tract [299]. 
However, patients develop chemoresistance over time due to several genetic 
and molecular alterations and no longer respond effectively to treatment. In 
such cases, patients are typically treated with a combination of agents to 
effectively overcome drug resistance [237].   
    Our in-vitro results clearly show that isorhamnetin could significantly 
enhance the cytotoxic effects of various chemotherapeutic agents, including 
capecitabine when used at a sub-optimal concentration in three different 
gastric cancer cell lines (Fig 3.6.2). To validate these findings in-vivo, we next 
analyzed the potential effect of isorhamnetin and capecitabine either alone, 
and/or in combination, on the growth of subcutaneously implanted human 
gastric cancer cells in nude mice. Interestingly, we found that isorhamnetin or 
capecitabine alone as well as the combination of the two agents could 
effectively reduce tumor volume in a xenograft model. Very few studies exist, 
to our knowledge, which have investigated the anti-cancer effects of 
isorhamnetin in mouse tumor models. One recent study showed that daily pre-
treatment of rats with isorhamnetin (5 mg/kg, i.p.) could significantly reduce 
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doxorubicin-induced myocardial damage and suppress the activation of 
mitochondrial apoptotic and mitogen-activated protein kinase pathways [300].  
Yet another study showed that isorhamnetin when administered at doses of 
(0.1 mg/kg and 0.5 mg/kg) significantly decreased tumor volume in C57BL/6 
mice that were subcutaneously implanted with Lewis lung cancer cells [138]. 
These are in accordance with our study, in which we demonstrate that 
isorhamnetin could significantly potentiate the tumor growth inhibition 
induced capecitabine in a xenograft model.   
         As described above, Ki-67 is a well-established proliferation biomarker 
while CD-31 is a marker associated with increase in angiogenesis. These 
markers have been regularly assessed in diverse tumor tissues using 
immunohistochemical assays [301].  Our data showed that isorhamnetin 
indeed could inhibit the expression of both Ki-67 and CD31 either alone and/ 
or in combination with capecitabine. VEGF, COX-2 and MMP-9 are proteins 
that play an important role in gastric cancer progression and invasion, hence 
we next examined if there was an alteration in the expression of these proteins 
after treatment of isorhamnetin in-vivo. As shown in Fig. 3.6.4, isorhamnetin 
alone and/or in combination with capecitabine could down-regulate the 
expression of the various oncogenic proteins involved in gastric cancer 
progression.  
We also noted that there was a significant increase in the expression of 
PPARγ protein (Fig.3.6.5) in the tumor tissues upon treatment with 
isorhamnetin, and this was further increased in the mice group exposed to the 
combination of both isorhamnetin and capecitabine. Also, we noted no 
significant weight gain  in mice treated with isorhamnetin, a characteristic 
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side-effect observed with use of classical PPARγ agonists such as 
thiazolidinediones in cancer therapy [302]. Having identified BMPR2 as a 
potential target of PPARγ, we also determined whether its expression could be 
modulated in-vivo. Interestingly, we found that BMPR2 expression was 
significantly down-regulated in tumors treated with isorhamnetin as well as 
those exposed to the combination of both isorhamnetin and capecitabine.   
        The therapeutic efficacy of isorhamnetin in mouse tumor models has not 
been extensively studied, with few selective studies [134, 138, 139] that have 
attempted to understand its action in-vivo. Ours is therefore the first to analyze 
the effect of isorhamnetin in combination with chemotherapy in gastric cancer, 
and we show that isorhamnetin may have a significant potential for gastric 




               In our study, we report for the first time that isorhamnetin exhibits its 
anticancer effects in gastric cancer cells through the positive regulation of 
PPARγ signaling pathway. We observed that this flavonoid could reduce 
proliferation, induce apoptosis, inhibit epithelial to mesenchymal transition 
and chemosensitize gastric cancer cells to capecitabine in a xenograft mouse 
model.  
We postulate that this action of isorhamnetin is mediated at least in 
part through the activation of PPARγ and support the same providing multiple 
mechanistic evidences, to prove that it can, not only induce PPARγ activity, 
but also modulate the expression of the PPARγ regulated genes in gastric 
cancer cells.  Also, the increase in PPARγ activity by isorhamnetin could be 
partially reversed in the presence of PPARγ pharmacological blocker and a 
mutated PPARγ dominant negative plasmid, thereby indicating that 
isorhamnetin could act specifically towards activating PPARγ. We further 
observed that isorhamnetin could competitively bind to PPARγ and form 
interactions with 7 polar residues and 6 non-polar residues within the ligand-
binding pocket of PPAR-γ that are reported to be critical for its activity [161]. 
This hypothesis was also supported by a virtual predictive tumor cell system, 
where 0.5μM and 5μM concentrations of isorhamnetin were seen to cause 
PPARγ activation. 
                 To understand the possible molecular mechanism(s) of action of 
isorhamnetin, we evaluated its effect on the apoptosis in gastric cancer cells. 
We found that isorhamnetin was able to induce significant apoptosis 
concomitant with down-regulation in the expression of the various anti-
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apoptotic/anti-proliferative proteins (Bcl-2, Bcl-xL, and Cyclin-D1), and 
increase in PARP cleavage in a time dependent manner in gastric cancer cells.  
Cancer metastasis refers to the spread of cancer cells from the primary 
neoplasm to distant sites, where secondary tumors are formed, and remains the 
major cause of mortality in cancer patients. In this respect, our study is the 
first to demonstrate that isorhamnetin can indeed inhibit the migratory and 
invasive properties of gastric cancer cells in the presence of the chemokine, 
CXCL12. Along this line, we also show for the first time that isorhamnetin 
can inhibit EMT, which is an important phenomenon in angiogenesis, possibly 
via the abrogation of BMPR2 expression in gastric cancer cells. Ours is also 
the first study to suggest that BMPR2 is a possible target of PPARγ, and the 
inhibition of BMPR2 can significantly reduce migration and EMT in gastric 
cancer cells.  
          Whether these in-vitro observations with isorhamnetin have any 
relevance under in-vivo settings was also investigated. We used a xenograft 
model in which mice were treated either alone with isorhamnetin or 
capecitabine or with a combination of both agents. We noted that isorhamnetin 
could indeed chemosensitize gastric tumors to capecitabine, as observed by 
the effective down regulation of Ki-67, CD-31, VEGF, COX-2 and MMP-9 in 
tumor tumors. To the best of our knowledge, no prior studies with 
isorhamnetin in xenograft GC models have been reported so far, and our 
overall findings suggest that isorhamnetin has a tremendous potential in 
gastric cancer therapy.    
Thus, overall, our experimental and predictive experiment results 
clearly indicate that anti-proliferative, pro-apoptotic and chemosensitizing 
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effects of isorhamnetin in gastric cancer are mediated at least in part through 
the activation of transcription factor PPARγ and provide a sound basis for 
pursuing the use of isorhamnetin further, either alone or in combination with 
existing therapy, to reduce the side effects and promote treatment efficacy for 
gastric cancer.  
 
Figure 5.1. A schematic diagram representing the possible molecular 
mechanism of action of isorhamnetin in gastric cancer cells  
 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors that were first discovered 20 years ago. PPARγ, an 
isoform of PPAR, is highly expressed in cancer cells and treatment with 
PPARγ ligands is shown to induce cell differentiation and apoptosis. 
Isorhamnetin acts as a partial ligand of PPARγ, by interacting via two key 
residues, Cys 285 and Ser 289. Activated PPARγ binds to RXR, and interacts 
with co-repressors or co-activators. The complex further binds to selected 
PPRE regions in the DNA to regulate various genes.  
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Figure 5.2. A sschematic diagram of the various therapeutic roles of 





Isorhamnetin binds and activates PPARγ, which leads to modulation of 
various genes involved in proliferation, anti-apoptosis and angiogenesis. 
Through this figure, we show that isorhamnetin can inhibit proliferation by 
down-regulating CyclinD1, induce apoptosis by modulating the expression of 
Bcl-2, Bcl-XL and inducing cleavage of PARP, and finally inhibit epithelial-to 
mesenchymal transition via the down-regulation of EMT regulated genes and 
the expression of BMPR2. Thus, through the modulation of multiple 





6. FUTURE DIRECTIONS 
Our attempts to examine the effects of isorhamnetin are only the beginning of 
an elaborate research study to understand the anti-cancer effects of this 
promising metabolite. Even though our study has successfully demonstrated 
the preliminary anticancer mechanism(s) of isorhamnetin both in-vitro and in-
vivo, it is still important to identify the co-repressors and co-activators of 
PPARγ that are required for the optimum activity of this flavonoid.  Also, a 
comparative study that explores the detailed anti-cancer effects, 
pharmacokinetic properties and toxicological profiles of isorhamnetin and its 
parent compound, quercetin, side-by-side will definitely provide a clearer 
picture of the in vivo efficacy of the two drugs simultaneously. Lastly, our 
primary data reveals the potential of BMPR2 as a tumor-promoter and as a 
putative target gene of PPARγ. However, further knockdown studies are 
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2.2.3. Molecular docking analysis 
An X-ray crystallography structure of PPAR-γ (PDB ID: 2Q5S) was obtained 
from the RCSB Protein Data Bank. This structure was utilized in the study 
since it was found to have a relatively good resolution of 2.05Å, with R value 
of 0.199 and R free value of 0.245. The protein file contains two copies of 
PPAR-γ. The first copy, chain A was removed since it contained less residues 
than the second copy, chain B. The ligand associated with chain A and all 
water molecules were also removed. The remaining protein chain and its 
associated ligand were then processed using the default settings for the 
“Protonate 3D” feature in the software Molecular Operating Environment 
(MOE) to add hydrogen atoms and determine the ionization state of the 
residues. Molecular docking of IH to PPAR-γ was then performed using the 
Dock feature in MOE. The “Alpha PMI” algorithm was used to generate 250 
different poses for IH. Alpha HB scoring function was used to rank these 
poses. The top 10 poses were retained and further refined by energy 
minimization. The MMFF94x forcefield using Reaction Field model was used 
for the energy minimization. Side chains of residues with 6 Å from the ligand 
were allowed to move during energy minimization. After energy 
minimization, the pose with the best interaction energy with the receptor was 
retained, as described previously [303]. 
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3. RESULTS  
3.3.1. Molecular docking of isorhamnetin with PPARγ 
Fig.3.3.1 shows the ligand interaction map and pose of isorhamentin inside 
PPARγ. The complex of isorhamentin and PPARγ had interaction energy of -
27.73 kcal/mol. Isorhamentin was found to have interactions with 5 polar 
residues and 9 non-polar residues. Among these interactions, Cys 285 and Ser 




Supplementary fig 3.3.1: Isorhamnetin interacts with PPARγ 
 
The ligand interaction map of IH inside PPARγ (left) and 3D conformational 
structure of IH inside PPARγ (right).  IH interacts directly with PPARγ at 7 
polar residues and 6 non-polar residues out of which two residues, Cys285 and 
Ser289 were previously found to be important for its binding and activity. 
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9. APPENDIX-II  
 
2.2. Methods  
2.2.13 (A) Virtual predictive studies  
Predictive analysis was performed using the Virtual Tumor Cell technology, 
Cellworks Group Inc, CA, USA which has been extensively validated and 
aligned with cancer physiology.  The Cellworks Tumor cell platform provides 
a dynamic and transparent view of cancer disease cellular physiology at the 
functional proteomics abstraction level. The platform’s open-access 
architecture provides a framework for different ‘what-if’ analysis and studies 
in an automated high-throughput methodology. The Cellworks platform is 
implemented using a three-layered architecture. The top later is a TUI/GUI 
(Text user interface/graphic user interface) driven user interface. The middle 
layer is the comprehensive representation of signaling and metabolic pathways 
covering all cancer phenotypes. The bottom layer is the computational 
backplane which enables the system to be dynamic and computes all the 
mathematics in the middle layer. 
 
2.2.13 (B) Platform description   
The virtual Tumor Cell Platform consists of a dynamic and kinetic 
representation of the signaling pathways underlying tumor physiology at the 
bio-molecular level. All the key relevant protein players and associated gene 
and mRNA species with regard to tumor related signaling are 
comprehensively included in the system with their relationship quantitatively 
represented.  Pathways and signaling for different cancer phenotypes comprise 
20000 plus crosstalk with more than 8000 intracellular molecules.  The 
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platform includes important signaling pathways comprising growth factors 
like EGFR, PDGFRA, FGFR, c-MET, VEGFR and IGF-1R, cell cycle 
regulators, mTOR signaling, p53 signaling cascade, cytokine pathways like 
IL1, IL4, IL6, IL12, TNF; lipid mediators and tumor metabolism..Fig. S3.1 
(A) shows the customized Cellworks Tumor Cell Platform that was created to 
align to AGS human gastric cancer cell line (KRAS mutant, PI3KCA mutant, 
RUNX3 deleted, β-catenin mutant and CDH1 deleted). 
 
2.2.13 (C) Predictive Study Experimental Protocol 
The virtual Tumor cell is simulated in the proprietary Cellworks 
computational backplane and initialized to a control state wherein all 
molecules attain the control steady state values, following which the triggers 
are introduced into the system.  The virtual tumor cell technology allows the 
end user to align the system to a known cancer cell line with perturbations in 
known markers or mutations that can be used for further analysis. In this 
kinetic based virtual tumor cell platform, there is no statistical variation in the 
outputs.  The system provides predictive semi-quantitative trends visibility 
into all phenotypes and bio-markers.  The system predictions have been 
validated against a large number of retrospective and prospective studies and 
the accuracy of predictions is very high. 
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3. RESULTS  
3.1. In silico analysis of anti-cancer effects of isorhamnetin 
 
IH was observed to be an activator of PPAR gamma and tested at 
concentrations of 0.5μM and 5μM with a Ka of 1.19μM. (Fig. S3.1 (B)). 
Testing the effect of IH on anti-apoptotic genes such as Bcl-2, Bcl-xl, survivin 
and Mcl-1 showed positive results with IH down-regulating expression of 
these genes (Fig. S3.1 (C)). Of the two proliferative markers tested, CyclinD1 
was found to show a higher reduction when compared to Cyclin E on 
treatment with IH (Fig. S3.1 (D)). The impact of IH on angiogenic and 
metastatic markers VEGFA and CXCR4 was also studied and showed a 
reduction of ~55% and 45% with 5 μM of IH, respectively (Fig. S3.1 (E)). 
Caspases-9 and 3 were found to decrease significantly on treatment with IH 
(Fig. S3.1 (F)). Out of the apoptotic gene products, BAK showed a higher 
increase when compared to BAX (Fig. S3.1 (G)). Cleaved PARP1 was found 
to show a very high increase of ~2500% and ~5000% with 0.5 μM and 5 μM 








Supplementary fig 3.1: Predictive in silico Virtual Tumor Cell platform 
generated results:  
 
(A) The figure illustrates a high-level view of the maze of interactions and 
cross-talks present in the Virtual Tumor Cell platform. The Cellworks virtual 
epithelial tumor cell platform on which predictive studies were conducted, is 
an integrated representation of the pathways in cancer that includes 
phenotypes of proliferation, apoptosis, angiogenesis, metastasis and conditions 





(B) Increase in PPAR Gamma activity upon treatment with IH. (C) The figure 
depicts the effect of IH on survival markers-BCL2, BCL-xl, Survivin and 
MCL1. (D) The figure depicts the impact of IH on Proliferative markers-
CCND1 and CCNE. (E) The figure depicts the impact of IH on angiogenic and 




(F) The impact of IH on apoptotic markers- CASP3 and CASP9. (G) The 




10. APPENDIX –III 
 
2.2. Methods 
2.2.16 (A) Data preprocessing of Affymetrix microarray gene expression 
 Microarray data GSE15460 [Ooi2009], a collection of human gastric 
cancer on Affymetrix U133Plus2 platforms were downloaded from Gene 
Expression Omnibus (GEO) and normalized using Robust Multichip Average 
(RMA). 
2.2.16 (B) Epithelial-Mesenchymal Transition Scoring 
The computation of EMT scores was performed using single sample GSEA 
(ssGSEA) [Verhaak2013] and a gastric-cancer specific EMT signature derived 
[Tan2014]. Briefly, the up-regulated genes in epithelial and mesenchymal 
states were obtained by comparing gastric carcinoma cell lines expression 
profiling. A BinReg model [Gatza2010] was then built based on these up-
regulated genes to differentiate epithelial and mesenchymal gastric cell lines. 
Subsequently, the top 25% of the gastric cell lines with the highest 
probabilities for epithelial or mesenchymal phenotype were used to obtain the 
epithelial or mesenchymal specific gene list for the gastric cancer cell lines 
using Significance Analysis of Microarray (SAM) q-value =0 and ROC value 
of 0.85. The EMT score is defined as the normalized subtraction of the 
mesenchymal from epithelial enrichment score computed by ssGSEA. The 
EMT score ranges from -1.0 (fully epithelial) to +1.0 (fully mesenchymal).  
2.2.16 (C) Statistical analysis 
 Spearman correlation coefficient test was computed using Matlab®. 




3.7. Co-relation between BMPR2 and EMT  
As shown in Fig.3.7 (A), a comprehensive figure of gastric cell lines arranged 
according to EMT score was obtained through the analysis. They are shown to 
be arranged from the least epithelial to the most epithelial. We also observed 
that BMPR2 expression correlated positively to EMT score, indicating that 
higher expression of BMPR2 associates with higher possibility of EMT. 
Further, we observed that higher expression of BMPR2 had poor prognosis in 








Supplementary fig. 3.7 (A): Gastric cell lines arranged according to EMT 
score  
 
(A) EMT score (y-axis) of 39 gastric carcinoma cell lines (n=70; GSE15460) 




Supplementary fig. 3.7 (B): BMPR2 positively co-relates with EMT score  
 
(B) Scatter plot of the EMT score (y-axis) and BMPR2 gene expression (x-
axis) of 231 gastric carcinoma from GSE15460 cohort. A linear regression 
(red, dotted) line shows correlation between EMT score and BMPR2 




Supplementary fig. 3.7 (C): Prognostic significance of BMPR2 in gastric 
cancer 
 
Kaplan-Meier analyses of overall (C) and disease-specific survival (D) of 
gastric cancer patients stratified based on BMPR2 gene expression. Patients 
with BMPR2 gene expression < and ≥ median were grouped into BMPR2-low 
(blue) and BMPR2-high (red) respectively. The p-values were computed by 
log-rank test. 
